<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="interaction" /><meta name="keywords" content="" /><title>Antidepressants: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="59/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="PHP0-publication-information.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="bnf_int229-antidepressants.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="bnf_int229-antidepressants.htm#pB" title="Skip Navigation">Skip Navigation</a><img src="../../images/mylogo.png" alt="BNF.org Free Access" id="pI" /><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=bnf_int229-antidepressants.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 06 Oct 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF September 2012</a> &gt; <a href="PHP8848-interactions.htm">Appendix 1 Interactions</a> &gt; <a href="PHP8852-list-of-drug-interactions.htm">List of drug interactions</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="bnf_int228-tinzaparin.htm" title="Previous: Tinzaparin">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="bnf_int1145-agomelatine.htm" title="Next: Agomelatine">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1>Antidepressants</h1><?highlighter on?><div id="pC" class="jN"><p><strong>Antidepressants</strong> has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int937-artemether-with-lumefantrine.htm">Artemether with Lumefantrine</a></td><td class="cAI"><p><span>avoidance of </span> <span>antidepressants</span> <span>advised by manufacturer of</span> <span>artemether/lumefantrine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1009-atomoxetine.htm">Atomoxetine</a></td><td><p><span>possible increased risk of convulsions when </span> <span>antidepressants</span> <span>given with</span> <span>atomoxetine</span> <span></span>  </p></td><td></td></tr></tbody></table><p><strong>Agomelatine</strong> belongs to <strong>Antidepressants</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int195-ciprofloxacin.htm">Ciprofloxacin</a></td><td class="cAI"><p><span>manufacturer of </span> <span>agomelatine</span> <span>advises avoid concomitant use with</span> <span>ciprofloxacin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int235-fluvoxamine.htm">Fluvoxamine</a></td><td class="cAI"><p><span>metabolism of </span> <span>agomelatine</span> <span>inhibited by</span> <span>fluvoxamine</span> <span>(increased plasma concentration)</span>  </p></td><td></td></tr></tbody></table><p><strong>Mirtazapine</strong> belongs to <strong>Antidepressants</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int20-alcohol.htm">Alcohol</a></td><td class="cAI"><p><span>increased sedative effect when </span> <span>mirtazapine</span> <span>given with</span> <span>alcohol</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int404-anxiolytics-and-hypnotics.htm">Anxiolytics and Hypnotics</a></td><td><p><span>increased sedative effect when </span> <span>mirtazapine</span> <span>given with</span> <span>anxiolytics and hypnotics</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int277-carbamazepine.htm">Carbamazepine</a></td><td><p><span>plasma concentration of </span> <span>mirtazapine</span> <span>reduced by</span> <span>carbamazepine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int744-cimetidine.htm">Cimetidine</a></td><td><p><span>plasma concentration of </span> <span>mirtazapine</span> <span>increased by</span> <span>cimetidine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int482-clonidine.htm">Clonidine</a></td><td><p><span></span> <span>mirtazapine</span> <span>possibly antagonises hypotensive effect of</span> <span>clonidine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int234-fluoxetine.htm">Fluoxetine</a></td><td><p><span>possible increased serotonergic effects when </span> <span>mirtazapine</span> <span>given with</span> <span>fluoxetine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int235-fluvoxamine.htm">Fluvoxamine</a></td><td><p><span>possible increased serotonergic effects when </span> <span>mirtazapine</span> <span>given with</span> <span>fluvoxamine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int298-ketoconazole.htm">Ketoconazole</a></td><td><p><span>plasma concentration of </span> <span>mirtazapine</span> <span>increased by</span> <span>ketoconazole</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int257-maois.htm">MAOIs</a></td><td class="cAI"><p><span></span> <span>mirtazapine</span> <span>should not be started until 2 weeks after stopping</span> <span>MAOIs</span> <span>, also <span>MAOIs</span> should not be started until at least 2 weeks after stopping <span>mirtazapine</span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> For interactions of reversible MAO-A inhibitors (RIMAs) see Moclobemide, and for interactions of MAO-B inhibitors see Rasagiline and Selegiline; the antibacterial Linezolid is a reversible, non-selective MAO inhibitor</p></div></td></tr><tr><td><a href="bnf_int1224-methylthioninium.htm">Methylthioninium</a></td><td class="cAI"><p><span>possible risk of CNS toxicity when </span> <span>mirtazapine</span> <span>given with</span> <span>methylthioninium</span> <span>—avoid concomitant use (if avoidance not possible, use lowest possible dose of <span>methylthioninium</span> and observe patient for up to 4 hours after administration)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int262-moclobemide.htm">Moclobemide</a></td><td class="cAI"><p><span>after stopping </span> <span>mirtazapine</span> <span>do not start</span> <span>moclobemide</span> <span>for at least 1 week</span>  </p></td><td></td></tr><tr><td><a href="bnf_int284-phenytoin.htm">Phenytoin</a></td><td><p><span>plasma concentration of </span> <span>mirtazapine</span> <span>reduced by</span> <span>phenytoin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int106-tramadol.htm">Tramadol</a></td><td><p><span>possible increased serotonergic effects when </span> <span>mirtazapine</span> <span>given with</span> <span>tramadol</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int240-venlafaxine.htm">Venlafaxine</a></td><td><p><span>possible increased serotonergic effects when </span> <span>mirtazapine</span> <span>given with</span> <span>venlafaxine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int222-warfarin.htm">Warfarin</a></td><td><p><span></span> <span>mirtazapine</span> <span>enhances anticoagulant effect of</span> <span>warfarin</span> <span></span>  </p></td><td></td></tr></tbody></table><p><strong>Antidepressants, Noradrenaline Re-uptake Inhibitors</strong> belongs to <strong>Antidepressants</strong> but has no specific interaction information.</p><p><strong>Reboxetine</strong> belongs to <strong>Antidepressants</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int293-antifungals-imidazole.htm">Antifungals, Imidazole</a></td><td class="cAI"><p><span>manufacturer of </span> <span>reboxetine</span> <span>advises avoid concomitant use with</span> <span>imidazoles</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int300-antifungals-triazole.htm">Antifungals, Triazole</a></td><td class="cAI"><p><span>manufacturer of </span> <span>reboxetine</span> <span>advises avoid concomitant use with</span> <span>triazoles</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int277-carbamazepine.htm">Carbamazepine</a></td><td><p><span>plasma concentration of </span> <span>reboxetine</span> <span>possibly reduced by</span> <span>carbamazepine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int539-diuretics-loop.htm">Diuretics, Loop</a></td><td><p><span>possible increased risk of hypokalaemia when </span> <span>reboxetine</span> <span>given with</span> <span>loop diuretics</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int525-diuretics-thiazide-and-related.htm">Diuretics, Thiazide and related</a></td><td><p><span>possible increased risk of hypokalaemia when </span> <span>reboxetine</span> <span>given with</span> <span>thiazides and related diuretics</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int563-ergotamine-and-methysergide.htm">Ergotamine and Methysergide</a></td><td><p><span>possible risk of hypertension when </span> <span>reboxetine</span> <span>given with</span> <span>ergotamine and methysergide</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int235-fluvoxamine.htm">Fluvoxamine</a></td><td class="cAI"><p><span>manufacturer of </span> <span>reboxetine</span> <span>advises avoid concomitant use with</span> <span>fluvoxamine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int257-maois.htm">MAOIs</a></td><td class="cAI"><p><span>increased risk of hypertension and CNS excitation when </span> <span>reboxetine</span> <span>given with</span> <span>MAOIs</span> <span>(<span>MAOIs</span> should not be started until 1 week after stopping <span>reboxetine</span>, avoid <span>reboxetine</span> for 2 weeks after stopping <span>MAOIs</span>)</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> For interactions of reversible MAO-A inhibitors (RIMAs) see Moclobemide, and for interactions of MAO-B inhibitors see Rasagiline and Selegiline; the antibacterial Linezolid is a reversible, non-selective MAO inhibitor</p></div></td></tr><tr><td><a href="bnf_int166-macrolides.htm">Macrolides</a></td><td class="cAI"><p><span>manufacturer of </span> <span>reboxetine</span> <span>advises avoid concomitant use with</span> <span>macrolides</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> See also Telithromycin</p></div></td></tr><tr><td><a href="bnf_int437-phenobarbital.htm">Phenobarbital</a></td><td><p><span>plasma concentration of </span> <span>reboxetine</span> <span>possibly reduced by</span> <span>phenobarbital</span> <span></span>  </p></td><td></td></tr></tbody></table><p><strong>Antidepressants, SSRI</strong> belongs to <strong>Antidepressants</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int20-alcohol.htm">Alcohol</a></td><td><p><span>sedative effects possibly increased when </span> <span>SSRIs</span> <span>given with</span> <span>alcohol</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int241-antidepressants-tricyclic.htm">Antidepressants, Tricyclic</a></td><td class="cAI"><p><span></span> <span>SSRIs</span> <span>increase plasma concentration of some</span> <span>tricyclics</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int276-antiepileptics.htm">Antiepileptics</a></td><td class="cAI"><p><span></span> <span>SSRIs</span> <span>antagonise anticonvulsant effect of</span> <span>antiepileptics</span> <span>(convulsive threshold lowered)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int361-aspirin.htm">Aspirin</a></td><td class="cAI"><p><span>increased risk of bleeding when </span> <span>SSRIs</span> <span>given with</span> <span>aspirin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int220-coumarins.htm">Coumarins</a></td><td class="cAI"><p><span></span> <span>SSRIs</span> <span>possibly enhance anticoagulant effect of</span> <span>coumarins</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Change in patient's clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</p></div></td></tr><tr><td><a href="bnf_int317-cyproheptadine.htm">Cyproheptadine</a></td><td><p><span>antidepressant effect of </span> <span>SSRIs</span> <span>possibly antagonised by</span> <span>cyproheptadine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1024-duloxetine.htm">Duloxetine</a></td><td><p><span>possible increased serotonergic effects when </span> <span>SSRIs</span> <span>given with</span> <span>duloxetine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int372-lithium.htm">Lithium</a></td><td class="cAI"><p><span>Increased risk of CNS effects when </span> <span>SSRIs</span> <span>given with</span> <span>lithium</span> <span>(<span>lithium</span> toxicity reported)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int257-maois.htm">MAOIs</a></td><td class="cAI"><p><span>CNS effects of </span> <span>SSRIs</span> <span>increased by</span> <span>MAOIs</span> <span>(risk of serious toxicity)</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> For interactions of reversible MAO-A inhibitors (RIMAs) see Moclobemide, and for interactions of MAO-B inhibitors see Rasagiline and Selegiline; the antibacterial Linezolid is a reversible, non-selective MAO inhibitor</p></div></td></tr><tr><td><a href="bnf_int718-methylphenidate.htm">Methylphenidate</a></td><td><p><span>metabolism of </span> <span>SSRIs</span> <span>possibly inhibited by</span> <span>methylphenidate</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1224-methylthioninium.htm">Methylthioninium</a></td><td class="cAI"><p><span>risk of CNS toxicity when </span> <span>SSRIs</span> <span>given with</span> <span>methylthioninium</span> <span>—avoid concomitant use (if avoidance not possible, use lowest possible dose of <span>methylthioninium</span> and observe patient for up to 4 hours after administration)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int613-metoclopramide.htm">Metoclopramide</a></td><td><p><span>CNS toxicity reported when </span> <span>SSRIs</span> <span>given with</span> <span>metoclopramide</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int60-nsaids.htm">NSAIDs</a></td><td class="cAI"><p><span>increased risk of bleeding when </span> <span>SSRIs</span> <span>given with</span> <span>NSAIDs</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> See also Aspirin. Interactions do not generally apply to topical NSAIDs
</p></div></td></tr><tr><td><a href="bnf_int573-naratriptan.htm">Naratriptan</a></td><td><p><span>possible increased serotonergic effects when </span> <span>SSRIs</span> <span>given with</span> <span>naratriptan</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int369-pimozide.htm">Pimozide</a></td><td class="cAI"><p><span></span> <span>SSRIs</span> <span>possibly increase plasma concentration of</span> <span>pimozide</span> <span>(increased risk of ventricular arrhythmias—avoid concomitant use)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1051-rasagiline.htm">Rasagiline</a></td><td class="cAI"><p><span>increased risk of CNS toxicity when </span> <span>SSRIs</span> <span>given with</span> <span>rasagiline</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Rasagiline is a MAO-B inhibitor</p></div></td></tr><tr><td><a href="bnf_int400-ritonavir.htm">Ritonavir</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>SSRIs</span> <span>possibly increased by</span> <span>ritonavir</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int905-st-johns-wort.htm">St John's Wort</a></td><td class="cAI"><p><span>increased serotonergic effects when </span> <span>SSRIs</span> <span>given with</span> <span>St John's wort</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int106-tramadol.htm">Tramadol</a></td><td class="cAI"><p><span>increased risk of CNS toxicity when </span> <span>SSRIs</span> <span>given with</span> <span>tramadol</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int263-tryptophan.htm">Tryptophan</a></td><td class="cAI"><p><span>agitation and nausea may occur when </span> <span>SSRIs</span> <span>given with</span> <span>tryptophan</span> <span></span>  </p></td><td></td></tr></tbody></table><p><strong>Escitalopram</strong> belongs to <strong>Antidepressants</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int744-cimetidine.htm">Cimetidine</a></td><td><p><span>plasma concentration of </span> <span>escitalopram</span> <span>increased by</span> <span>cimetidine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int257-maois.htm">MAOIs</a></td><td class="cAI"><p><span></span> <span>escitalopram</span> <span>should not be started until 2 weeks after stopping</span> <span>MAOIs</span> <span>, also <span>MAOIs</span> should not be started until at least 1 week after stopping <span>escitalopram</span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> For interactions of reversible MAO-A inhibitors (RIMAs) see Moclobemide, and for interactions of MAO-B inhibitors see Rasagiline and Selegiline; the antibacterial Linezolid is a reversible, non-selective MAO inhibitor</p></div></td></tr><tr><td><a href="bnf_int451-metoprolol.htm">Metoprolol</a></td><td><p><span></span> <span>escitalopram</span> <span>increases plasma concentration of</span> <span>metoprolol</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int262-moclobemide.htm">Moclobemide</a></td><td class="cAI"><p><span>increased risk of CNS toxicity when </span> <span>escitalopram</span> <span>given with</span> <span>moclobemide</span> <span>, preferably avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int752-omeprazole.htm">Omeprazole</a></td><td><p><span>plasma concentration of </span> <span>escitalopram</span> <span>increased by</span> <span>omeprazole</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int687-selegiline.htm">Selegiline</a></td><td><p><span>avoidance of </span> <span>escitalopram</span> <span>advised by manufacturer of</span> <span>selegiline</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Selegiline is a MAO-B inhibitor</p></div></td></tr><tr><td><a href="bnf_int574-sumatriptan.htm">Sumatriptan</a></td><td class="cAI"><p><span>increased risk of CNS toxicity when </span> <span>escitalopram</span> <span>given with</span> <span>sumatriptan</span> <span></span>  </p></td><td></td></tr></tbody></table><p><strong>Citalopram</strong> belongs to <strong>Antidepressants</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int572-5ht-1-receptor-agonists.htm">5HT<sub>1</sub>-receptor Agonists</a></td><td class="cAI"><p><span>increased risk of CNS toxicity when </span> <span>citalopram</span> <span>given with</span> <span>5HT<sub>1</sub> agonists</span> <span>(manufacturer of <span>citalopram</span> advises avoid concomitant use)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int896-bupropion.htm">Bupropion</a></td><td><p><span>plasma concentration of </span> <span>citalopram</span> <span>possibly increased by</span> <span>bupropion</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int744-cimetidine.htm">Cimetidine</a></td><td><p><span>plasma concentration of </span> <span>citalopram</span> <span>increased by</span> <span>cimetidine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int364-clozapine.htm">Clozapine</a></td><td><p><span></span> <span>citalopram</span> <span>possibly increases plasma concentration of</span> <span>clozapine</span> <span>(increased risk of toxicity)</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Avoid concomitant use of clozapine with drugs that have a substantial potential for causing agranulocytosis</p></div></td></tr><tr><td><a href="bnf_int257-maois.htm">MAOIs</a></td><td class="cAI"><p><span></span> <span>citalopram</span> <span>should not be started until 2 weeks after stopping</span> <span>MAOIs</span> <span>, also <span>MAOIs</span> should not be started until at least 1 week after stopping <span>citalopram</span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> For interactions of reversible MAO-A inhibitors (RIMAs) see Moclobemide, and for interactions of MAO-B inhibitors see Rasagiline and Selegiline; the antibacterial Linezolid is a reversible, non-selective MAO inhibitor</p></div></td></tr><tr><td><a href="bnf_int451-metoprolol.htm">Metoprolol</a></td><td><p><span></span> <span>citalopram</span> <span>increases plasma concentration of</span> <span>metoprolol</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int262-moclobemide.htm">Moclobemide</a></td><td class="cAI"><p><span>after stopping </span> <span>citalopram</span> <span>do not start</span> <span>moclobemide</span> <span>for at least 1 week</span>  </p></td><td></td></tr><tr><td><a href="bnf_int687-selegiline.htm">Selegiline</a></td><td><p><span>avoidance of </span> <span>citalopram</span> <span>advised by manufacturer of</span> <span>selegiline</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Selegiline is a MAO-B inhibitor</p></div></td></tr><tr><td><a href="bnf_int574-sumatriptan.htm">Sumatriptan</a></td><td class="cAI"><p><span>increased risk of CNS toxicity when </span> <span>citalopram</span> <span>given with</span> <span>sumatriptan</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1203-ticagrelor.htm">Ticagrelor</a></td><td><p><span>possible increased risk of bleeding when </span> <span>citalopram</span> <span>given with</span> <span>ticagrelor</span> <span></span>  </p></td><td></td></tr></tbody></table><p><strong>Fluoxetine</strong> belongs to <strong>Antidepressants</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int406-alprazolam.htm">Alprazolam</a></td><td><p><span></span> <span>fluoxetine</span> <span>increases plasma concentration of</span> <span>alprazolam</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1011-aripiprazole.htm">Aripiprazole</a></td><td class="cAI"><p><span></span> <span>fluoxetine</span> <span>possibly inhibits metabolism of</span> <span>aripiprazole</span> <span>(reduce dose of <span>aripiprazole</span>)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1009-atomoxetine.htm">Atomoxetine</a></td><td><p><span></span> <span>fluoxetine</span> <span>possibly inhibits metabolism of</span> <span>atomoxetine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int277-carbamazepine.htm">Carbamazepine</a></td><td class="cAI"><p><span></span> <span>fluoxetine</span> <span>increases plasma concentration of</span> <span>carbamazepine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int865-clopidogrel.htm">Clopidogrel</a></td><td class="cAI"><p><span></span> <span>fluoxetine</span> <span>possibly reduces antiplatelet effect of</span> <span>clopidogrel</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int364-clozapine.htm">Clozapine</a></td><td class="cAI"><p><span></span> <span>fluoxetine</span> <span>increases plasma concentration of</span> <span>clozapine</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Avoid concomitant use of clozapine with drugs that have a substantial potential for causing agranulocytosis</p></div></td></tr><tr><td><a href="bnf_int1152-droperidol.htm">Droperidol</a></td><td class="cAI"><p><span>avoidance of </span> <span>fluoxetine</span> <span>advised by manufacturer of</span> <span>droperidol</span> <span>(risk of ventricular arrhythmias)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int120-flecainide.htm">Flecainide</a></td><td><p><span></span> <span>fluoxetine</span> <span>increases plasma concentration of</span> <span>flecainide</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int387-haloperidol.htm">Haloperidol</a></td><td class="cAI"><p><span></span> <span>fluoxetine</span> <span>increases plasma concentration of</span> <span>haloperidol</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int257-maois.htm">MAOIs</a></td><td class="cAI"><p><span></span> <span>fluoxetine</span> <span>should not be started until 2 weeks after stopping</span> <span>MAOIs</span> <span>, also <span>MAOIs</span> should not be started until at least 5 weeks after stopping <span>fluoxetine</span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> For interactions of reversible MAO-A inhibitors (RIMAs) see Moclobemide, and for interactions of MAO-B inhibitors see Rasagiline and Selegiline; the antibacterial Linezolid is a reversible, non-selective MAO inhibitor</p></div></td></tr><tr><td><a href="bnf_int97-methadone.htm">Methadone</a></td><td><p><span></span> <span>fluoxetine</span> <span>possibly increases plasma concentration of</span> <span>methadone</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int823-mirtazapine.htm">Mirtazapine</a></td><td><p><span>possible increased serotonergic effects when </span> <span>fluoxetine</span> <span>given with</span> <span>mirtazapine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int262-moclobemide.htm">Moclobemide</a></td><td class="cAI"><p><span>after stopping </span> <span>fluoxetine</span> <span>do not start</span> <span>moclobemide</span> <span>for 5 weeks</span>  </p></td><td></td></tr><tr><td><a href="bnf_int475-nifedipine.htm">Nifedipine</a></td><td><p><span></span> <span>fluoxetine</span> <span>possibly inhibits metabolism of</span> <span>nifedipine</span> <span>(increased plasma concentration)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int284-phenytoin.htm">Phenytoin</a></td><td class="cAI"><p><span></span> <span>fluoxetine</span> <span>increases plasma concentration of</span> <span>phenytoin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1051-rasagiline.htm">Rasagiline</a></td><td class="cAI"><p><span></span> <span>fluoxetine</span> <span>should not be started until 2 weeks after stopping</span> <span>rasagiline</span> <span>, also <span>rasagiline</span> should not be started until at least 5 weeks after stopping <span>fluoxetine</span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Rasagiline is a MAO-B inhibitor</p></div></td></tr><tr><td><a href="bnf_int368-risperidone.htm">Risperidone</a></td><td><p><span></span> <span>fluoxetine</span> <span>increases plasma concentration of</span> <span>risperidone</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int687-selegiline.htm">Selegiline</a></td><td class="cAI"><p><span>increased risk of hypertension and CNS excitation when </span> <span>fluoxetine</span> <span>given with</span> <span>selegiline</span> <span>(<span>selegiline</span> should not be started until 5 weeks after stopping <span>fluoxetine</span>, avoid <span>fluoxetine</span> for 2 weeks after stopping <span>selegiline</span>)</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Selegiline is a MAO-B inhibitor</p></div></td></tr><tr><td><a href="bnf_int574-sumatriptan.htm">Sumatriptan</a></td><td class="cAI"><p><span>increased risk of CNS toxicity when </span> <span>fluoxetine</span> <span>given with</span> <span>sumatriptan</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int581-tamoxifen.htm">Tamoxifen</a></td><td class="cAI"><p><span></span> <span>fluoxetine</span> <span>possibly inhibits metabolism of</span> <span>tamoxifen</span> <span>to active metabolite (avoid concomitant use)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int263-tryptophan.htm">Tryptophan</a></td><td><p><span>CNS toxicity reported when </span> <span>fluoxetine</span> <span>given with</span> <span>tryptophan</span> <span></span>  </p></td><td></td></tr></tbody></table><p><strong>Fluvoxamine</strong> belongs to <strong>Antidepressants</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int1145-agomelatine.htm">Agomelatine</a></td><td class="cAI"><p><span></span> <span>fluvoxamine</span> <span>inhibits metabolism of</span> <span>agomelatine</span> <span>(increased plasma concentration)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1209-asenapine.htm">Asenapine</a></td><td><p><span></span> <span>fluvoxamine</span> <span>possibly increases plasma concentration of</span> <span>asenapine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int405-benzodiazepines.htm">Benzodiazepines</a></td><td><p><span></span> <span>fluvoxamine</span> <span>increases plasma concentration of some</span> <span>benzodiazepines</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int277-carbamazepine.htm">Carbamazepine</a></td><td class="cAI"><p><span></span> <span>fluvoxamine</span> <span>increases plasma concentration of</span> <span>carbamazepine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int865-clopidogrel.htm">Clopidogrel</a></td><td class="cAI"><p><span></span> <span>fluvoxamine</span> <span>possibly reduces antiplatelet effect of</span> <span>clopidogrel</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int364-clozapine.htm">Clozapine</a></td><td class="cAI"><p><span></span> <span>fluvoxamine</span> <span>increases plasma concentration of</span> <span>clozapine</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Avoid concomitant use of clozapine with drugs that have a substantial potential for causing agranulocytosis</p></div></td></tr><tr><td><a href="bnf_int1152-droperidol.htm">Droperidol</a></td><td class="cAI"><p><span>avoidance of </span> <span>fluvoxamine</span> <span>advised by manufacturer of</span> <span>droperidol</span> <span>(risk of ventricular arrhythmias)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1024-duloxetine.htm">Duloxetine</a></td><td class="cAI"><p><span></span> <span>fluvoxamine</span> <span>inhibits metabolism of</span> <span>duloxetine</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int965-frovatriptan.htm">Frovatriptan</a></td><td><p><span></span> <span>fluvoxamine</span> <span>inhibits the metabolism of</span> <span>frovatriptan</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int387-haloperidol.htm">Haloperidol</a></td><td><p><span></span> <span>fluvoxamine</span> <span>possibly increases plasma concentration of</span> <span>haloperidol</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int753-lansoprazole.htm">Lansoprazole</a></td><td><p><span></span> <span>fluvoxamine</span> <span>possibly increases plasma concentration of</span> <span>lansoprazole</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int257-maois.htm">MAOIs</a></td><td class="cAI"><p><span></span> <span>fluvoxamine</span> <span>should not be started until 2 weeks after stopping</span> <span>MAOIs</span> <span>, also <span>MAOIs</span> should not be started until at least 1 week after stopping <span>fluvoxamine</span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> For interactions of reversible MAO-A inhibitors (RIMAs) see Moclobemide, and for interactions of MAO-B inhibitors see Rasagiline and Selegiline; the antibacterial Linezolid is a reversible, non-selective MAO inhibitor</p></div></td></tr><tr><td><a href="bnf_int1114-melatonin.htm">Melatonin</a></td><td class="cAI"><p><span></span> <span>fluvoxamine</span> <span>increases plasma concentration of</span> <span>melatonin</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int97-methadone.htm">Methadone</a></td><td><p><span></span> <span>fluvoxamine</span> <span>possibly increases plasma concentration of</span> <span>methadone</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int823-mirtazapine.htm">Mirtazapine</a></td><td><p><span>possible increased serotonergic effects when </span> <span>fluvoxamine</span> <span>given with</span> <span>mirtazapine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int262-moclobemide.htm">Moclobemide</a></td><td class="cAI"><p><span>after stopping </span> <span>fluvoxamine</span> <span>do not start</span> <span>moclobemide</span> <span>for at least 1 week</span>  </p></td><td></td></tr><tr><td><a href="bnf_int366-olanzapine.htm">Olanzapine</a></td><td><p><span></span> <span>fluvoxamine</span> <span>increases plasma concentration of</span> <span>olanzapine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int284-phenytoin.htm">Phenytoin</a></td><td class="cAI"><p><span></span> <span>fluvoxamine</span> <span>increases plasma concentration of</span> <span>phenytoin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int793-propranolol.htm">Propranolol</a></td><td><p><span></span> <span>fluvoxamine</span> <span>increases plasma concentration of</span> <span>propranolol</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1051-rasagiline.htm">Rasagiline</a></td><td class="cAI"><p><span></span> <span>fluvoxamine</span> <span>should not be started until 2 weeks after stopping</span> <span>rasagiline</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Rasagiline is a MAO-B inhibitor</p></div></td></tr><tr><td><a href="bnf_int231-reboxetine.htm">Reboxetine</a></td><td class="cAI"><p><span>avoidance of </span> <span>fluvoxamine</span> <span>advised by manufacturer of</span> <span>reboxetine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1190-roflumilast.htm">Roflumilast</a></td><td><p><span></span> <span>fluvoxamine</span> <span>inhibits the metabolism of</span> <span>roflumilast</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int888-ropivacaine.htm">Ropivacaine</a></td><td><p><span></span> <span>fluvoxamine</span> <span>inhibits metabolism of</span> <span>ropivacaine</span> <span>—avoid prolonged administration of <span>ropivacaine</span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int687-selegiline.htm">Selegiline</a></td><td class="cAI"><p><span>increased risk of hypertension and CNS excitation when </span> <span>fluvoxamine</span> <span>given with</span> <span>selegiline</span> <span>(<span>selegiline</span> should not be started until 1 week after stopping <span>fluvoxamine</span>, avoid <span>fluvoxamine</span> for 2 weeks after stopping <span>selegiline</span>)</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Selegiline is a MAO-B inhibitor</p></div></td></tr><tr><td><a href="bnf_int574-sumatriptan.htm">Sumatriptan</a></td><td class="cAI"><p><span>increased risk of CNS toxicity when </span> <span>fluvoxamine</span> <span>given with</span> <span>sumatriptan</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int734-theophylline.htm">Theophylline</a></td><td class="cAI"><p><span></span> <span>fluvoxamine</span> <span>increases plasma concentration of</span> <span>theophylline</span> <span>(concomitant use should usually be avoided, but where not possible halve <span>theophylline</span> dose and monitor plasma-<span>theophylline</span> concentration)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int805-tizanidine.htm">Tizanidine</a></td><td class="cAI"><p><span></span> <span>fluvoxamine</span> <span>increases plasma concentration of</span> <span>tizanidine</span> <span>(increased risk of toxicity)—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int575-zolmitriptan.htm">Zolmitriptan</a></td><td><p><span></span> <span>fluvoxamine</span> <span>possibly inhibits metabolism of</span> <span>zolmitriptan</span> <span>(reduce dose of <span>zolmitriptan</span>)</span>  </p></td><td></td></tr></tbody></table><p><strong>Paroxetine</strong> belongs to <strong>Antidepressants</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int1011-aripiprazole.htm">Aripiprazole</a></td><td class="cAI"><p><span></span> <span>paroxetine</span> <span>possibly inhibits metabolism of</span> <span>aripiprazole</span> <span>(reduce dose of <span>aripiprazole</span>)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1209-asenapine.htm">Asenapine</a></td><td><p><span>plasma concentration of </span> <span>paroxetine</span> <span>possibly increased by</span> <span>asenapine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1009-atomoxetine.htm">Atomoxetine</a></td><td><p><span></span> <span>paroxetine</span> <span>possibly inhibits metabolism of</span> <span>atomoxetine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int364-clozapine.htm">Clozapine</a></td><td class="cAI"><p><span></span> <span>paroxetine</span> <span>increases plasma concentration of</span> <span>clozapine</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Avoid concomitant use of clozapine with drugs that have a substantial potential for causing agranulocytosis</p></div></td></tr><tr><td><a href="bnf_int1076-darifenacin.htm">Darifenacin</a></td><td><p><span></span> <span>paroxetine</span> <span>increases plasma concentration of</span> <span>darifenacin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1091-darunavir.htm">Darunavir</a></td><td><p><span>plasma concentration of </span> <span>paroxetine</span> <span>possibly reduced by</span> <span>darunavir</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int915-galantamine.htm">Galantamine</a></td><td><p><span></span> <span>paroxetine</span> <span>increases plasma concentration of</span> <span>galantamine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int257-maois.htm">MAOIs</a></td><td class="cAI"><p><span></span> <span>paroxetine</span> <span>should not be started until 2 weeks after stopping</span> <span>MAOIs</span> <span>, also <span>MAOIs</span> should not be started until at least 1 week after stopping <span>paroxetine</span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> For interactions of reversible MAO-A inhibitors (RIMAs) see Moclobemide, and for interactions of MAO-B inhibitors see Rasagiline and Selegiline; the antibacterial Linezolid is a reversible, non-selective MAO inhibitor</p></div></td></tr><tr><td><a href="bnf_int97-methadone.htm">Methadone</a></td><td><p><span></span> <span>paroxetine</span> <span>possibly increases plasma concentration of</span> <span>methadone</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int451-metoprolol.htm">Metoprolol</a></td><td><p><span></span> <span>paroxetine</span> <span>possibly increases plasma concentration of</span> <span>metoprolol</span> <span>(enhanced effect)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int262-moclobemide.htm">Moclobemide</a></td><td class="cAI"><p><span>after stopping </span> <span>paroxetine</span> <span>do not start</span> <span>moclobemide</span> <span>for at least 1 week</span>  </p></td><td></td></tr><tr><td><a href="bnf_int381-perphenazine.htm">Perphenazine</a></td><td><p><span></span> <span>paroxetine</span> <span>inhibits metabolism of</span> <span>perphenazine</span> <span>(reduce dose of <span>perphenazine</span>)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int437-phenobarbital.htm">Phenobarbital</a></td><td><p><span>plasma concentration of </span> <span>paroxetine</span> <span>reduced by</span> <span>phenobarbital</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int284-phenytoin.htm">Phenytoin</a></td><td><p><span>plasma concentration of </span> <span>paroxetine</span> <span>reduced by</span> <span>phenytoin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int354-procyclidine.htm">Procyclidine</a></td><td><p><span></span> <span>paroxetine</span> <span>increases plasma concentration of</span> <span>procyclidine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int125-propafenone.htm">Propafenone</a></td><td><p><span></span> <span>paroxetine</span> <span>possibly inhibits metabolism of</span> <span>propafenone</span> <span>(increased risk of toxicity)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1147-ranolazine.htm">Ranolazine</a></td><td><p><span></span> <span>paroxetine</span> <span>increases plasma concentration of</span> <span>ranolazine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int368-risperidone.htm">Risperidone</a></td><td><p><span></span> <span>paroxetine</span> <span>possibly increases plasma concentration of</span> <span>risperidone</span> <span>(increased risk of toxicity)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int400-ritonavir.htm">Ritonavir</a></td><td><p><span>plasma concentration of </span> <span>paroxetine</span> <span>possibly reduced by</span> <span>ritonavir</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int687-selegiline.htm">Selegiline</a></td><td class="cAI"><p><span>increased risk of hypertension and CNS excitation when </span> <span>paroxetine</span> <span>given with</span> <span>selegiline</span> <span>(<span>selegiline</span> should not be started until 2 weeks after stopping <span>paroxetine</span>, avoid <span>paroxetine</span> for 2 weeks after stopping <span>selegiline</span>)</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Selegiline is a MAO-B inhibitor</p></div></td></tr><tr><td><a href="bnf_int574-sumatriptan.htm">Sumatriptan</a></td><td class="cAI"><p><span>increased risk of CNS toxicity when </span> <span>paroxetine</span> <span>given with</span> <span>sumatriptan</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int581-tamoxifen.htm">Tamoxifen</a></td><td class="cAI"><p><span></span> <span>paroxetine</span> <span>possibly inhibits metabolism of</span> <span>tamoxifen</span> <span>to active metabolite (avoid concomitant use)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1203-ticagrelor.htm">Ticagrelor</a></td><td><p><span>possible increased risk of bleeding when </span> <span>paroxetine</span> <span>given with</span> <span>ticagrelor</span> <span></span>  </p></td><td></td></tr></tbody></table><p><strong>Sertraline</strong> belongs to <strong>Antidepressants</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int744-cimetidine.htm">Cimetidine</a></td><td><p><span>plasma concentration of </span> <span>sertraline</span> <span>increased by</span> <span>cimetidine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int364-clozapine.htm">Clozapine</a></td><td class="cAI"><p><span></span> <span>sertraline</span> <span>increases plasma concentration of</span> <span>clozapine</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Avoid concomitant use of clozapine with drugs that have a substantial potential for causing agranulocytosis</p></div></td></tr><tr><td><a href="bnf_int1091-darunavir.htm">Darunavir</a></td><td><p><span>plasma concentration of </span> <span>sertraline</span> <span>possibly reduced by</span> <span>darunavir</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1152-droperidol.htm">Droperidol</a></td><td class="cAI"><p><span>avoidance of </span> <span>sertraline</span> <span>advised by manufacturer of</span> <span>droperidol</span> <span>(risk of ventricular arrhythmias)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int829-grapefruit-juice.htm">Grapefruit Juice</a></td><td><p><span>plasma concentration of </span> <span>sertraline</span> <span>possibly increased by</span> <span>grapefruit juice</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int257-maois.htm">MAOIs</a></td><td class="cAI"><p><span></span> <span>sertraline</span> <span>should not be started until 2 weeks after stopping</span> <span>MAOIs</span> <span>, also <span>MAOIs</span> should not be started until at least 1 week after stopping <span>sertraline</span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> For interactions of reversible MAO-A inhibitors (RIMAs) see Moclobemide, and for interactions of MAO-B inhibitors see Rasagiline and Selegiline; the antibacterial Linezolid is a reversible, non-selective MAO inhibitor</p></div></td></tr><tr><td><a href="bnf_int97-methadone.htm">Methadone</a></td><td><p><span></span> <span>sertraline</span> <span>possibly increases plasma concentration of</span> <span>methadone</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int262-moclobemide.htm">Moclobemide</a></td><td class="cAI"><p><span>after stopping </span> <span>sertraline</span> <span>do not start</span> <span>moclobemide</span> <span>for at least 1 week</span>  </p></td><td></td></tr><tr><td><a href="bnf_int284-phenytoin.htm">Phenytoin</a></td><td><p><span>plasma concentration of </span> <span>sertraline</span> <span>possibly reduced by</span> <span>phenytoin</span> <span>, also plasma concentration of <span>phenytoin</span> possibly increased</span>  </p></td><td></td></tr><tr><td><a href="bnf_int687-selegiline.htm">Selegiline</a></td><td class="cAI"><p><span>increased risk of hypertension and CNS excitation when </span> <span>sertraline</span> <span>given with</span> <span>selegiline</span> <span>(<span>selegiline</span> should not be started until 1 week after stopping <span>sertraline</span>, avoid <span>sertraline</span> for 2 weeks after stopping <span>selegiline</span>)</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Selegiline is a MAO-B inhibitor</p></div></td></tr><tr><td><a href="bnf_int574-sumatriptan.htm">Sumatriptan</a></td><td><p><span>CNS toxicity reported when </span> <span>sertraline</span> <span>given with</span> <span>sumatriptan</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1203-ticagrelor.htm">Ticagrelor</a></td><td><p><span>possible increased risk of bleeding when </span> <span>sertraline</span> <span>given with</span> <span>ticagrelor</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int425-zolpidem.htm">Zolpidem</a></td><td><p><span>sedative effects possibly increased when </span> <span>sertraline</span> <span>given with</span> <span>zolpidem</span> <span></span>  </p></td><td></td></tr></tbody></table><p><strong>Antidepressants, SSRI (related)</strong> belongs to <strong>Antidepressants</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int1224-methylthioninium.htm">Methylthioninium</a></td><td class="cAI"><p><span>risk of CNS toxicity when </span> <span>SSRI-related antidepressants</span> <span>given with</span> <span>methylthioninium</span> <span>—avoid concomitant use (if avoidance not possible, use lowest possible dose of <span>methylthioninium</span> and observe patient for up to 4 hours after administration)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int262-moclobemide.htm">Moclobemide</a></td><td class="cAI"><p><span>after stopping </span> <span>SSRI-related antidepressants</span> <span>do not start</span> <span>moclobemide</span> <span>for at least 1 week</span>  </p></td><td></td></tr></tbody></table><p><strong>Duloxetine</strong> belongs to <strong>Antidepressants</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int572-5ht-1-receptor-agonists.htm">5HT<sub>1</sub>-receptor Agonists</a></td><td><p><span>possible increased serotonergic effects when </span> <span>duloxetine</span> <span>given with</span> <span>5HT<sub>1</sub> agonists</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int242-amitriptyline.htm">Amitriptyline</a></td><td><p><span>possible increased serotonergic effects when </span> <span>duloxetine</span> <span>given with</span> <span>amitriptyline</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int232-antidepressants-ssri.htm">Antidepressants, SSRI</a></td><td><p><span>possible increased serotonergic effects when </span> <span>duloxetine</span> <span>given with</span> <span>SSRIs</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int195-ciprofloxacin.htm">Ciprofloxacin</a></td><td class="cAI"><p><span>metabolism of </span> <span>duloxetine</span> <span>inhibited by</span> <span>ciprofloxacin</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int244-clomipramine.htm">Clomipramine</a></td><td><p><span>possible increased serotonergic effects when </span> <span>duloxetine</span> <span>given with</span> <span>clomipramine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int235-fluvoxamine.htm">Fluvoxamine</a></td><td class="cAI"><p><span>metabolism of </span> <span>duloxetine</span> <span>inhibited by</span> <span>fluvoxamine</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int257-maois.htm">MAOIs</a></td><td class="cAI"><p><span></span> <span>duloxetine</span> <span>should not be started until 2 weeks after stopping</span> <span>MAOIs</span> <span>, also <span>MAOIs</span> should not be started until at least 5 days after stopping <span>duloxetine</span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> For interactions of reversible MAO-A inhibitors (RIMAs) see Moclobemide, and for interactions of MAO-B inhibitors see Rasagiline and Selegiline; the antibacterial Linezolid is a reversible, non-selective MAO inhibitor</p></div></td></tr><tr><td><a href="bnf_int262-moclobemide.htm">Moclobemide</a></td><td class="cAI"><p><span>possible increased serotonergic effects when </span> <span>duloxetine</span> <span>given with</span> <span>moclobemide</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int102-pethidine.htm">Pethidine</a></td><td><p><span>possible increased serotonergic effects when </span> <span>duloxetine</span> <span>given with</span> <span>pethidine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int905-st-johns-wort.htm">St John's Wort</a></td><td><p><span>possible increased serotonergic effects when </span> <span>duloxetine</span> <span>given with</span> <span>St John's wort</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int106-tramadol.htm">Tramadol</a></td><td><p><span>possible increased serotonergic effects when </span> <span>duloxetine</span> <span>given with</span> <span>tramadol</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int263-tryptophan.htm">Tryptophan</a></td><td><p><span>possible increased serotonergic effects when </span> <span>duloxetine</span> <span>given with</span> <span>tryptophan</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int240-venlafaxine.htm">Venlafaxine</a></td><td><p><span>possible increased serotonergic effects when </span> <span>duloxetine</span> <span>given with</span> <span>venlafaxine</span> <span></span>  </p></td><td></td></tr></tbody></table><p><strong>Venlafaxine</strong> belongs to <strong>Antidepressants</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int572-5ht-1-receptor-agonists.htm">5HT<sub>1</sub>-receptor Agonists</a></td><td><p><span>possible increased serotonergic effects when </span> <span>venlafaxine</span> <span>given with</span> <span>5HT<sub>1</sub> agonists</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int361-aspirin.htm">Aspirin</a></td><td class="cAI"><p><span>increased risk of bleeding when </span> <span>venlafaxine</span> <span>given with</span> <span>aspirin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int364-clozapine.htm">Clozapine</a></td><td class="cAI"><p><span></span> <span>venlafaxine</span> <span>increases plasma concentration of</span> <span>clozapine</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Avoid concomitant use of clozapine with drugs that have a substantial potential for causing agranulocytosis</p></div></td></tr><tr><td><a href="bnf_int1024-duloxetine.htm">Duloxetine</a></td><td><p><span>possible increased serotonergic effects when </span> <span>venlafaxine</span> <span>given with</span> <span>duloxetine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int854-entacapone.htm">Entacapone</a></td><td><p><span>caution with </span> <span>venlafaxine</span> <span>advised by manufacturer of</span> <span>entacapone</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int387-haloperidol.htm">Haloperidol</a></td><td><p><span></span> <span>venlafaxine</span> <span>increases plasma concentration of</span> <span>haloperidol</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int372-lithium.htm">Lithium</a></td><td><p><span>possible increased serotonergic effects when </span> <span>venlafaxine</span> <span>given with</span> <span>lithium</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int257-maois.htm">MAOIs</a></td><td class="cAI"><p><span>enhanced CNS effects and toxicity when </span> <span>venlafaxine</span> <span>given with</span> <span>MAOIs</span> <span>(<span>venlafaxine</span> should not be started until 2 weeks after stopping <span>MAOIs</span>, avoid <span>MAOIs</span> for 1 week after stopping <span>venlafaxine</span>)</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> For interactions of reversible MAO-A inhibitors (RIMAs) see Moclobemide, and for interactions of MAO-B inhibitors see Rasagiline and Selegiline; the antibacterial Linezolid is a reversible, non-selective MAO inhibitor</p></div></td></tr><tr><td><a href="bnf_int823-mirtazapine.htm">Mirtazapine</a></td><td><p><span>possible increased serotonergic effects when </span> <span>venlafaxine</span> <span>given with</span> <span>mirtazapine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int60-nsaids.htm">NSAIDs</a></td><td class="cAI"><p><span>increased risk of bleeding when </span> <span>venlafaxine</span> <span>given with</span> <span>NSAIDs</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> See also Aspirin. Interactions do not generally apply to topical NSAIDs
</p></div></td></tr><tr><td><a href="bnf_int687-selegiline.htm">Selegiline</a></td><td class="cAI"><p><span>increased risk of hypertension and CNS excitation when </span> <span>venlafaxine</span> <span>given with</span> <span>selegiline</span> <span>(<span>selegiline</span> should not be started until 1 week after stopping <span>venlafaxine</span>, avoid <span>venlafaxine</span> for 2 weeks after stopping <span>selegiline</span>)</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Selegiline is a MAO-B inhibitor</p></div></td></tr><tr><td><a href="bnf_int905-st-johns-wort.htm">St John's Wort</a></td><td><p><span>possible increased serotonergic effects when </span> <span>venlafaxine</span> <span>given with</span> <span>St John's wort</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int106-tramadol.htm">Tramadol</a></td><td><p><span>possible increased serotonergic effects when </span> <span>venlafaxine</span> <span>given with</span> <span>tramadol</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int222-warfarin.htm">Warfarin</a></td><td class="cAI"><p><span></span> <span>venlafaxine</span> <span>possibly enhances anticoagulant effect of</span> <span>warfarin</span> <span></span>  </p></td><td></td></tr></tbody></table><p><strong>Antidepressants, Tricyclic</strong> belongs to <strong>Antidepressants</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int715-adrenaline-epinephrine.htm">Adrenaline (epinephrine)</a></td><td class="cAI"><p><span>increased risk of hypertension and arrhythmias when </span> <span>tricyclics</span> <span>given with</span> <span>adrenaline (epinephrine)</span> <span>(but local anaesthetics with adrenaline appear to be safe)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int15-adrenergic-neurone-blockers.htm">Adrenergic Neurone Blockers</a></td><td><p><span></span> <span>tricyclics</span> <span>antagonise hypotensive effect of</span> <span>adrenergic neurone blockers</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int20-alcohol.htm">Alcohol</a></td><td class="cAI"><p><span>increased sedative effect when </span> <span>tricyclics</span> <span>given with</span> <span>alcohol</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int118-amiodarone.htm">Amiodarone</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>tricyclics</span> <span>given with</span> <span>amiodarone</span> <span>—avoid concomitant use</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Amiodarone has a long half-life; there is a potential for drug interactions to occur for several weeks (or even months) after treatment with it has been stopped</p></div></td></tr><tr><td><a href="bnf_int39-anaesthetics-general.htm">Anaesthetics, General</a></td><td><p><span>increased risk of arrhythmias and hypotension when </span> <span>tricyclics</span> <span>given with</span> <span>general anaesthetics</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> See also Surgery and Long-term Medication, 
<a title="target-block: surgery and long term med" href="PHP8495-general-anaesthesia.htm#PHP8498">section 15.1</a>



</p></div></td></tr><tr><td><a href="bnf_int232-antidepressants-ssri.htm">Antidepressants, SSRI</a></td><td class="cAI"><p><span>plasma concentration of some </span> <span>tricyclics</span> <span>increased by</span> <span>SSRIs</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int276-antiepileptics.htm">Antiepileptics</a></td><td class="cAI"><p><span></span> <span>tricyclics</span> <span>antagonise anticonvulsant effect of</span> <span>antiepileptics</span> <span>(convulsive threshold lowered)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int303-antihistamines.htm">Antihistamines</a></td><td><p><span>increased antimuscarinic and sedative effects when </span> <span>tricyclics</span> <span>given with</span> <span>antihistamines</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Sedative interactions apply to a lesser extent to the non-sedating antihistamines. Interactions do not generally apply to antihistamines used for topical action (including inhalation)</p></div></td></tr><tr><td><a href="bnf_int342-antimuscarinics.htm">Antimuscarinics</a></td><td><p><span>increased risk of antimuscarinic side-effects when </span> <span>tricyclics</span> <span>given with</span> <span>antimuscarinics</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Many drugs have antimuscarinic effects; concomitant use of two or more such drugs can increase side-effects such as dry mouth, urine retention, and constipation; concomitant use can also lead to confusion in the elderly. Interactions do not generally apply to antimuscarinics used by inhalation</p></div></td></tr><tr><td><a href="bnf_int363-antipsychotics.htm">Antipsychotics</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>tricyclics</span> <span>increased by</span> <span>antipsychotics</span> <span>—possibly increased risk of ventricular arrhythmias</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Increased risk of toxicity with myelosuppressive drugs</p></div></td></tr><tr><td><a href="bnf_int404-anxiolytics-and-hypnotics.htm">Anxiolytics and Hypnotics</a></td><td><p><span>increased sedative effect when </span> <span>tricyclics</span> <span>given with</span> <span>anxiolytics and hypnotics</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int24-apraclonidine.htm">Apraclonidine</a></td><td><p><span>avoidance of </span> <span>tricyclics</span> <span>advised by manufacturer of</span> <span>apraclonidine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1009-atomoxetine.htm">Atomoxetine</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>tricyclics</span> <span>given with</span> <span>atomoxetine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int617-baclofen.htm">Baclofen</a></td><td><p><span></span> <span>tricyclics</span> <span>enhance muscle relaxant effect of</span> <span>baclofen</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int25-brimonidine.htm">Brimonidine</a></td><td><p><span>avoidance of </span> <span>tricyclics</span> <span>advised by manufacturer of</span> <span>brimonidine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int896-bupropion.htm">Bupropion</a></td><td><p><span>plasma concentration of </span> <span>tricyclics</span> <span>possibly increased by</span> <span>bupropion</span> <span>(possible increased risk of convulsions)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1189-cannabis-extract.htm">Cannabis Extract</a></td><td><p><span>possible increased risk of hypertension and tachycardia when </span> <span>tricyclics</span> <span>given with</span> <span>cannabis extract</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int277-carbamazepine.htm">Carbamazepine</a></td><td class="cAI"><p><span>metabolism of </span> <span>tricyclics</span> <span>accelerated by</span> <span>carbamazepine</span> <span>(reduced plasma concentration and reduced effect)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int744-cimetidine.htm">Cimetidine</a></td><td><p><span>plasma concentration of </span> <span>tricyclics</span> <span>possibly increased by</span> <span>cimetidine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int482-clonidine.htm">Clonidine</a></td><td class="cAI"><p><span></span> <span>tricyclics</span> <span>antagonise hypotensive effect of</span> <span>clonidine</span> <span>, also increased risk of hypertension on <span>clonidine</span> withdrawal</span>  </p></td><td></td></tr><tr><td><a href="bnf_int364-clozapine.htm">Clozapine</a></td><td><p><span>possible increased antimuscarinic side-effects when </span> <span>tricyclics</span> <span>given with</span> <span>clozapine</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Avoid concomitant use of clozapine with drugs that have a substantial potential for causing agranulocytosis</p></div></td></tr><tr><td><a href="bnf_int220-coumarins.htm">Coumarins</a></td><td class="cAI"><p><span></span> <span>tricyclics</span> <span>may enhance or reduce anticoagulant effect of</span> <span>coumarins</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Change in patient's clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</p></div></td></tr><tr><td><a href="bnf_int468-diltiazem.htm">Diltiazem</a></td><td><p><span>plasma concentration of </span> <span>tricyclics</span> <span>possibly increased by</span> <span>diltiazem</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int119-disopyramide.htm">Disopyramide</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>tricyclics</span> <span>given with</span> <span>disopyramide</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int523-disulfiram.htm">Disulfiram</a></td><td><p><span>metabolism of </span> <span>tricyclics</span> <span>inhibited by</span> <span>disulfiram</span> <span>(increased plasma concentration)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int524-diuretics.htm">Diuretics</a></td><td><p><span>increased risk of postural hypotension when </span> <span>tricyclics</span> <span>given with</span> <span>diuretics</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1176-dronedarone.htm">Dronedarone</a></td><td class="cAI"><p><span>avoidance of </span> <span>tricyclics</span> <span>advised by manufacturer of</span> <span>dronedarone</span> <span>(risk of ventricular arrhythmias)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1152-droperidol.htm">Droperidol</a></td><td class="cAI"><p><span>avoidance of </span> <span>tricyclics</span> <span>advised by manufacturer of</span> <span>droperidol</span> <span>(risk of ventricular arrhythmias)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int854-entacapone.htm">Entacapone</a></td><td><p><span>caution with </span> <span>tricyclics</span> <span>advised by manufacturer of</span> <span>entacapone</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int120-flecainide.htm">Flecainide</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>tricyclics</span> <span>given with</span> <span>flecainide</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1180-histamine.htm">Histamine</a></td><td><p><span></span> <span>tricyclics</span> <span>theoretically antagonise effects of</span> <span>histamine</span> <span>—manufacturer of <span>histamine</span> advises avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int372-lithium.htm">Lithium</a></td><td><p><span>risk of toxicity when </span> <span>tricyclics</span> <span>given with</span> <span>lithium</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int257-maois.htm">MAOIs</a></td><td class="cAI"><p><span>increased risk of hypertension and CNS excitation when </span> <span>tricyclics</span> <span>given with</span> <span>MAOIs</span> <span>, <span>tricyclics</span> should not be started until 2 weeks after stopping <span>MAOIs</span> (3 weeks if starting clomipramine or imipramine), also <span>MAOIs</span> should not be started for at least 1–2 weeks after stopping <span>tricyclics</span> (3 weeks in the case of clomipramine or imipramine)</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> For interactions of reversible MAO-A inhibitors (RIMAs) see Moclobemide, and for interactions of MAO-B inhibitors see Rasagiline and Selegiline; the antibacterial Linezolid is a reversible, non-selective MAO inhibitor</p></div></td></tr><tr><td><a href="bnf_int718-methylphenidate.htm">Methylphenidate</a></td><td><p><span>metabolism of </span> <span>tricyclics</span> <span>possibly inhibited by</span> <span>methylphenidate</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int262-moclobemide.htm">Moclobemide</a></td><td class="cAI"><p><span>after stopping </span> <span>tricyclics</span> <span>do not start</span> <span>moclobemide</span> <span>for at least 1 week</span>  </p></td><td></td></tr><tr><td><a href="bnf_int973-moxifloxacin.htm">Moxifloxacin</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>tricyclics</span> <span>given with</span> <span>moxifloxacin</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int615-moxonidine.htm">Moxonidine</a></td><td><p><span></span> <span>tricyclics</span> <span>possibly antagonise hypotensive effect of</span> <span>moxonidine</span> <span>(manufacturer of <span>moxonidine</span> advises avoid concomitant use)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int58-nefopam.htm">Nefopam</a></td><td><p><span>side-effects possibly increased when </span> <span>tricyclics</span> <span>given with</span> <span>nefopam</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int630-nicorandil.htm">Nicorandil</a></td><td><p><span></span> <span>tricyclics</span> <span>possibly enhance hypotensive effect of</span> <span>nicorandil</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int631-nitrates.htm">Nitrates</a></td><td><p><span></span> <span>tricyclics</span> <span>reduce effects of sublingual tablets of</span> <span>nitrates</span> <span>(failure to dissolve under tongue owing to dry mouth)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int711-noradrenaline-norepinephrine.htm">Noradrenaline (norepinephrine)</a></td><td class="cAI"><p><span>increased risk of hypertension and arrhythmias when </span> <span>tricyclics</span> <span>given with</span> <span>noradrenaline (norepinephrine)</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int636-oestrogens.htm">Oestrogens</a></td><td><p><span>antidepressant effect of </span> <span>tricyclics</span> <span>antagonised by</span> <span>oestrogens</span> <span>(but side-effects of <span>tricyclics</span>  possibly increased due to increased plasma concentration)</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Interactions of combined oral contraceptives may also apply to combined contraceptive patches and vaginal rings, see <a title="COCs interactions (target-block)" href="PHP4869-combined-hormonal-contraceptives.htm#PHP4875">section 7.3.1</a></p></div></td></tr><tr><td><a href="bnf_int85-opioid-analgesics.htm">Opioid Analgesics</a></td><td><p><span>sedative effects possibly increased when </span> <span>tricyclics</span> <span>given with</span> <span>opioid analgesics</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int808-pentamidine-isetionate.htm">Pentamidine Isetionate</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>tricyclics</span> <span>given with</span> <span>pentamidine isetionate</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int437-phenobarbital.htm">Phenobarbital</a></td><td class="cAI"><p><span>metabolism of </span> <span>tricyclics</span> <span>possibly accelerated by</span> <span>phenobarbital</span> <span>(reduced plasma concentration)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int373-phenothiazines.htm">Phenothiazines</a></td><td><p><span>increased risk of antimuscarinic side-effects when </span> <span>tricyclics</span> <span>given with</span> <span>phenothiazines</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int284-phenytoin.htm">Phenytoin</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>tricyclics</span> <span>possibly reduced by</span> <span>phenytoin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int369-pimozide.htm">Pimozide</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>tricyclics</span> <span>given with</span> <span>pimozide</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int125-propafenone.htm">Propafenone</a></td><td class="cAI"><p><span>increased risk of arrhythmias when </span> <span>tricyclics</span> <span>given with</span> <span>propafenone</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1051-rasagiline.htm">Rasagiline</a></td><td class="cAI"><p><span>increased risk of CNS toxicity when </span> <span>tricyclics</span> <span>given with</span> <span>rasagiline</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Rasagiline is a MAO-B inhibitor</p></div></td></tr><tr><td><a href="bnf_int400-ritonavir.htm">Ritonavir</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>tricyclics</span> <span>possibly increased by</span> <span>ritonavir</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int791-saquinavir.htm">Saquinavir</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>tricyclics</span> <span>given with</span> <span>saquinavir</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int687-selegiline.htm">Selegiline</a></td><td class="cAI"><p><span>CNS toxicity reported when </span> <span>tricyclics</span> <span>given with</span> <span>selegiline</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Selegiline is a MAO-B inhibitor</p></div></td></tr><tr><td><a href="bnf_int1067-sodium-oxybate.htm">Sodium Oxybate</a></td><td><p><span>increased risk of side-effects when </span> <span>tricyclics</span> <span>given with</span> <span>sodium oxybate</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int455-sotalol.htm">Sotalol</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>tricyclics</span> <span>given with</span> <span>sotalol</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int292-terbinafine.htm">Terbinafine</a></td><td><p><span>plasma concentration of </span> <span>tricyclics</span> <span>possibly increased by</span> <span>terbinafine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int935-thyroid-hormones.htm">Thyroid Hormones</a></td><td><p><span>effects of </span> <span>tricyclics</span> <span>possibly enhanced by</span> <span>thyroid hormones</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int106-tramadol.htm">Tramadol</a></td><td class="cAI"><p><span>increased risk of CNS toxicity when </span> <span>tricyclics</span> <span>given with</span> <span>tramadol</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int467-verapamil.htm">Verapamil</a></td><td><p><span>plasma concentration of </span> <span>tricyclics</span> <span>possibly increased by</span> <span>verapamil</span> <span></span>  </p></td><td></td></tr></tbody></table><p><strong>Amitriptyline</strong> belongs to <strong>Antidepressants</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int1168-arsenic-trioxide.htm">Arsenic Trioxide</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>amitriptyline</span> <span>given with</span> <span>arsenic trioxide</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int744-cimetidine.htm">Cimetidine</a></td><td><p><span>metabolism of </span> <span>amitriptyline</span> <span>inhibited by</span> <span>cimetidine</span> <span>(increased plasma concentration)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int523-disulfiram.htm">Disulfiram</a></td><td><p><span>concomitant </span> <span>amitriptyline</span> <span>reported to increase</span> <span>disulfiram</span> <span>reaction with alcohol</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1024-duloxetine.htm">Duloxetine</a></td><td><p><span>possible increased serotonergic effects when </span> <span>amitriptyline</span> <span>given with</span> <span>duloxetine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int301-fluconazole.htm">Fluconazole</a></td><td><p><span>plasma concentration of </span> <span>amitriptyline</span> <span>possibly increased by</span> <span>fluconazole</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> In general, fluconazole interactions relate to multiple-dose treatment</p></div></td></tr><tr><td><a href="bnf_int905-st-johns-wort.htm">St John's Wort</a></td><td><p><span>plasma concentration of </span> <span>amitriptyline</span> <span>reduced by</span> <span>St John's wort</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int935-thyroid-hormones.htm">Thyroid Hormones</a></td><td><p><span>effects of </span> <span>amitriptyline</span> <span>enhanced by</span> <span>thyroid hormones</span> <span></span>  </p></td><td></td></tr></tbody></table><p><strong>Clomipramine</strong> belongs to <strong>Antidepressants</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int1168-arsenic-trioxide.htm">Arsenic Trioxide</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>clomipramine</span> <span>given with</span> <span>arsenic trioxide</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1024-duloxetine.htm">Duloxetine</a></td><td><p><span>possible increased serotonergic effects when </span> <span>clomipramine</span> <span>given with</span> <span>duloxetine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1224-methylthioninium.htm">Methylthioninium</a></td><td class="cAI"><p><span>risk of CNS toxicity when </span> <span>clomipramine</span> <span>given with</span> <span>methylthioninium</span> <span>—avoid concomitant use (if avoidance not possible, use lowest possible dose of <span>methylthioninium</span> and observe patient for up to 4 hours after administration)</span>  </p></td><td></td></tr></tbody></table><p><strong>Dosulepin</strong> belongs to <strong>Antidepressants</strong> but has no specific interaction information.</p><p><strong>Doxepin</strong> belongs to <strong>Antidepressants</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int744-cimetidine.htm">Cimetidine</a></td><td><p><span>metabolism of </span> <span>doxepin</span> <span>inhibited by</span> <span>cimetidine</span> <span>(increased plasma concentration)</span>  </p></td><td></td></tr></tbody></table><p><strong>Imipramine</strong> belongs to <strong>Antidepressants</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int744-cimetidine.htm">Cimetidine</a></td><td><p><span>metabolism of </span> <span>imipramine</span> <span>inhibited by</span> <span>cimetidine</span> <span>(increased plasma concentration)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int468-diltiazem.htm">Diltiazem</a></td><td><p><span>plasma concentration of </span> <span>imipramine</span> <span>increased by</span> <span>diltiazem</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int448-labetalol.htm">Labetalol</a></td><td><p><span>plasma concentration of </span> <span>imipramine</span> <span>increased by</span> <span>labetalol</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int793-propranolol.htm">Propranolol</a></td><td><p><span>plasma concentration of </span> <span>imipramine</span> <span>increased by</span> <span>propranolol</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int935-thyroid-hormones.htm">Thyroid Hormones</a></td><td><p><span>effects of </span> <span>imipramine</span> <span>enhanced by</span> <span>thyroid hormones</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int467-verapamil.htm">Verapamil</a></td><td><p><span>plasma concentration of </span> <span>imipramine</span> <span>increased by</span> <span>verapamil</span> <span></span>  </p></td><td></td></tr></tbody></table><p><strong>Lofepramine</strong> belongs to <strong>Antidepressants</strong> but has no specific interaction information.</p><p><strong>Nortriptyline</strong> belongs to <strong>Antidepressants</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int744-cimetidine.htm">Cimetidine</a></td><td><p><span>metabolism of </span> <span>nortriptyline</span> <span>inhibited by</span> <span>cimetidine</span> <span>(increased plasma concentration)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int301-fluconazole.htm">Fluconazole</a></td><td><p><span>plasma concentration of </span> <span>nortriptyline</span> <span>possibly increased by</span> <span>fluconazole</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> In general, fluconazole interactions relate to multiple-dose treatment</p></div></td></tr></tbody></table><p><strong>Trimipramine</strong> belongs to <strong>Antidepressants</strong> but has no specific interaction information.</p><p><strong>Antidepressants, Tricyclic (related)</strong> belongs to <strong>Antidepressants</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int20-alcohol.htm">Alcohol</a></td><td class="cAI"><p><span>increased sedative effect when </span> <span>tricyclic-related antidepressants</span> <span>given with</span> <span>alcohol</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int276-antiepileptics.htm">Antiepileptics</a></td><td class="cAI"><p><span></span> <span>tricyclic-related antidepressants</span> <span>possibly antagonise anticonvulsant effect of</span> <span>antiepileptics</span> <span>(convulsive threshold lowered)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int303-antihistamines.htm">Antihistamines</a></td><td><p><span>possible increased antimuscarinic and sedative effects when </span> <span>tricyclic-related antidepressants</span> <span>given with</span> <span>antihistamines</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Sedative interactions apply to a lesser extent to the non-sedating antihistamines. Interactions do not generally apply to antihistamines used for topical action (including inhalation)</p></div></td></tr><tr><td><a href="bnf_int342-antimuscarinics.htm">Antimuscarinics</a></td><td><p><span>possible increased antimuscarinic side-effects when </span> <span>tricyclic-related antidepressants</span> <span>given with</span> <span>antimuscarinics</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Many drugs have antimuscarinic effects; concomitant use of two or more such drugs can increase side-effects such as dry mouth, urine retention, and constipation; concomitant use can also lead to confusion in the elderly. Interactions do not generally apply to antimuscarinics used by inhalation</p></div></td></tr><tr><td><a href="bnf_int404-anxiolytics-and-hypnotics.htm">Anxiolytics and Hypnotics</a></td><td><p><span>increased sedative effect when </span> <span>tricyclic-related antidepressants</span> <span>given with</span> <span>anxiolytics and hypnotics</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int24-apraclonidine.htm">Apraclonidine</a></td><td><p><span>avoidance of </span> <span>tricyclic-related antidepressants</span> <span>advised by manufacturer of</span> <span>apraclonidine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int25-brimonidine.htm">Brimonidine</a></td><td><p><span>avoidance of </span> <span>tricyclic-related antidepressants</span> <span>advised by manufacturer of</span> <span>brimonidine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int522-diazoxide.htm">Diazoxide</a></td><td><p><span>enhanced hypotensive effect when </span> <span>tricyclic-related antidepressants</span> <span>given with</span> <span>diazoxide</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int763-hydralazine.htm">Hydralazine</a></td><td><p><span>enhanced hypotensive effect when </span> <span>tricyclic-related antidepressants</span> <span>given with</span> <span>hydralazine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int257-maois.htm">MAOIs</a></td><td class="cAI"><p><span></span> <span>tricyclic-related antidepressants</span> <span>should not be started until 2 weeks after stopping</span> <span>MAOIs</span> <span>, also <span>MAOIs</span> should not be started until at least 1–2 weeks after stopping <span>tricyclic-related antidepressants</span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> For interactions of reversible MAO-A inhibitors (RIMAs) see Moclobemide, and for interactions of MAO-B inhibitors see Rasagiline and Selegiline; the antibacterial Linezolid is a reversible, non-selective MAO inhibitor</p></div></td></tr><tr><td><a href="bnf_int262-moclobemide.htm">Moclobemide</a></td><td class="cAI"><p><span>after stopping </span> <span>tricyclic-related antidepressants</span> <span>do not start</span> <span>moclobemide</span> <span>for at least 1 week</span>  </p></td><td></td></tr><tr><td><a href="bnf_int631-nitrates.htm">Nitrates</a></td><td><p><span></span> <span>tricyclic-related antidepressants</span> <span>possibly reduce effects of sublingual tablets of</span> <span>nitrates</span> <span>(failure to dissolve under tongue owing to dry mouth)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int765-sodium-nitroprusside.htm">Sodium Nitroprusside</a></td><td><p><span>enhanced hypotensive effect when </span> <span>tricyclic-related antidepressants</span> <span>given with</span> <span>sodium nitroprusside</span> <span></span>  </p></td><td></td></tr></tbody></table><p><strong>Mianserin</strong> belongs to <strong>Antidepressants</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int277-carbamazepine.htm">Carbamazepine</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>mianserin</span> <span>reduced by</span> <span>carbamazepine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int437-phenobarbital.htm">Phenobarbital</a></td><td class="cAI"><p><span>metabolism of </span> <span>mianserin</span> <span>accelerated by</span> <span>phenobarbital</span> <span>(reduced plasma concentration)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int284-phenytoin.htm">Phenytoin</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>mianserin</span> <span>reduced by</span> <span>phenytoin</span> <span></span>  </p></td><td></td></tr></tbody></table><p><strong>Trazodone</strong> belongs to <strong>Antidepressants</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int277-carbamazepine.htm">Carbamazepine</a></td><td><p><span>plasma concentration of </span> <span>trazodone</span> <span>reduced by</span> <span>carbamazepine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int168-clarithromycin.htm">Clarithromycin</a></td><td><p><span>plasma concentration of </span> <span>trazodone</span> <span>possibly increased by</span> <span>clarithromycin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int400-ritonavir.htm">Ritonavir</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>trazodone</span> <span>increased by</span> <span>ritonavir</span> <span>(increased risk of toxicity)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int791-saquinavir.htm">Saquinavir</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>trazodone</span> <span>given with</span> <span>saquinavir</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1216-telaprevir.htm">Telaprevir</a></td><td><p><span>plasma concentration of </span> <span>trazodone</span> <span>possibly increased by</span> <span>telaprevir</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int222-warfarin.htm">Warfarin</a></td><td><p><span></span> <span>trazodone</span> <span>may enhance or reduce anticoagulant effect of</span> <span>warfarin</span> <span></span>  </p></td><td></td></tr></tbody></table><p><strong>MAOIs</strong> belongs to <strong>Antidepressants</strong> and has the following interaction information:</p><div class="cG"><p><strong>Note:</strong> For interactions of reversible MAO-A inhibitors (RIMAs) see Moclobemide, and for interactions of MAO-B inhibitors see Rasagiline and Selegiline; the antibacterial Linezolid is a reversible, non-selective MAO inhibitor</p></div><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int2-ace-inhibitors.htm">ACE Inhibitors</a></td><td><p><span></span> <span>MAOIs</span> <span>possibly enhance hypotensive effect of</span> <span>ACE inhibitors</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int15-adrenergic-neurone-blockers.htm">Adrenergic Neurone Blockers</a></td><td><p><span>enhanced hypotensive effect when </span> <span>MAOIs</span> <span>given with</span> <span>adrenergic neurone blockers</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int20-alcohol.htm">Alcohol</a></td><td class="cAI"><p><span></span> <span>MAOIs</span> <span>interact with tyramine found in some beverages containing</span> <span>alcohol</span> <span>and some dealcoholised beverages (hypertensive crisis)—if no tyramine, enhanced hypotensive effect</span>  </p></td><td></td></tr><tr><td><a href="bnf_int26-alpha-blockers.htm">Alpha-blockers</a></td><td><p><span>enhanced hypotensive effect when </span> <span>MAOIs</span> <span>given with</span> <span>alpha-blockers</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int107-angiotensin-ii-receptor-antagonists.htm">Angiotensin-II Receptor Antagonists</a></td><td><p><span></span> <span>MAOIs</span> <span>possibly enhance hypotensive effect of</span> <span>angiotensin-II receptor antagonists</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int232-antidepressants-ssri.htm">Antidepressants, SSRI</a></td><td class="cAI"><p><span></span> <span>MAOIs</span> <span>increase CNS effects of</span> <span>SSRIs</span> <span>(risk of serious toxicity)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int241-antidepressants-tricyclic.htm">Antidepressants, Tricyclic</a></td><td class="cAI"><p><span>increased risk of hypertension and CNS excitation when </span> <span>MAOIs</span> <span>given with</span> <span>tricyclics</span> <span>, <span>tricyclics</span> should not be started until 2 weeks after stopping <span>MAOIs</span> (3 weeks if starting clomipramine or imipramine), also <span>MAOIs</span> should not be started for at least 1–2 weeks after stopping <span>tricyclics</span> (3 weeks in the case of clomipramine or imipramine)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int252-antidepressants-tricyclic-related.htm">Antidepressants, Tricyclic (related)</a></td><td class="cAI"><p><span>after stopping </span> <span>MAOIs</span> <span>do not start</span> <span>tricyclic-related antidepressants</span> <span>for 2 weeks, also <span>MAOIs</span> should not be started until at least 1–2 weeks after stopping <span>tricyclic-related antidepressants</span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int264-antidiabetics.htm">Antidiabetics</a></td><td><p><span></span> <span>MAOIs</span> <span>possibly enhance hypoglycaemic effect of</span> <span>antidiabetics</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int276-antiepileptics.htm">Antiepileptics</a></td><td><p><span></span> <span>MAOIs</span> <span>possibly antagonise anticonvulsant effect of</span> <span>antiepileptics</span> <span>(convulsive threshold lowered)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int303-antihistamines.htm">Antihistamines</a></td><td><p><span>increased antimuscarinic and sedative effects when </span> <span>MAOIs</span> <span>given with</span> <span>antihistamines</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Sedative interactions apply to a lesser extent to the non-sedating antihistamines. Interactions do not generally apply to antihistamines used for topical action (including inhalation)</p></div></td></tr><tr><td><a href="bnf_int342-antimuscarinics.htm">Antimuscarinics</a></td><td><p><span>increased risk of antimuscarinic side-effects when </span> <span>MAOIs</span> <span>given with</span> <span>antimuscarinics</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Many drugs have antimuscarinic effects; concomitant use of two or more such drugs can increase side-effects such as dry mouth, urine retention, and constipation; concomitant use can also lead to confusion in the elderly. Interactions do not generally apply to antimuscarinics used by inhalation</p></div></td></tr><tr><td><a href="bnf_int24-apraclonidine.htm">Apraclonidine</a></td><td><p><span>avoidance of </span> <span>MAOIs</span> <span>advised by manufacturer of</span> <span>apraclonidine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1009-atomoxetine.htm">Atomoxetine</a></td><td class="cAI"><p><span>after stopping </span> <span>MAOIs</span> <span>do not start</span> <span>atomoxetine</span> <span>for 2 weeks, also <span>MAOIs</span> should not be started until at least 2 weeks after stopping <span>atomoxetine</span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int440-beta-blockers.htm">Beta-blockers</a></td><td><p><span>enhanced hypotensive effect when </span> <span>MAOIs</span> <span>given with</span> <span>beta-blockers</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Since systemic absorption may follow topical application of beta-blockers to the eye the possibility of interactions, in particular, with drugs such as verapamil should be borne in mind</p></div></td></tr><tr><td><a href="bnf_int25-brimonidine.htm">Brimonidine</a></td><td><p><span>avoidance of </span> <span>MAOIs</span> <span>advised by manufacturer of</span> <span>brimonidine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int896-bupropion.htm">Bupropion</a></td><td class="cAI"><p><span>avoidance of bupropion for 2 weeks after stopping </span> <span>MAOIs</span> <span>advised by manufacturer of</span> <span>bupropion</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int427-buspirone.htm">Buspirone</a></td><td><p><span>avoidance of </span> <span>MAOIs</span> <span>advised by manufacturer of</span> <span>buspirone</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int466-calcium-channel-blockers.htm">Calcium-channel Blockers</a></td><td><p><span>enhanced hypotensive effect when </span> <span>MAOIs</span> <span>given with</span> <span>calcium-channel blockers</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Dihydropyridine calcium-channel blockers include amlodipine, felodipine, isradipine, lacidipine, lercanidipine, nicardipine, nifedipine, and nimodipine</p></div></td></tr><tr><td><a href="bnf_int277-carbamazepine.htm">Carbamazepine</a></td><td class="cAI"><p><span>avoidance for 2 weeks after stopping </span> <span>MAOIs</span> <span>advised by manufacturer of</span> <span>carbamazepine</span> <span>, also antagonism of anticonvulsant effect</span>  </p></td><td></td></tr><tr><td><a href="bnf_int233-citalopram.htm">Citalopram</a></td><td class="cAI"><p><span>after stopping </span> <span>MAOIs</span> <span>do not start</span> <span>citalopram</span> <span>for 2 weeks, also <span>MAOIs</span> should not be started until at least 1 week after stopping <span>citalopram</span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int482-clonidine.htm">Clonidine</a></td><td><p><span>enhanced hypotensive effect when </span> <span>MAOIs</span> <span>given with</span> <span>clonidine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int364-clozapine.htm">Clozapine</a></td><td class="cAI"><p><span>CNS effects of </span> <span>MAOIs</span> <span>possibly increased by</span> <span>clozapine</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Avoid concomitant use of clozapine with drugs that have a substantial potential for causing agranulocytosis</p></div></td></tr><tr><td><a href="bnf_int522-diazoxide.htm">Diazoxide</a></td><td><p><span>enhanced hypotensive effect when </span> <span>MAOIs</span> <span>given with</span> <span>diazoxide</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int524-diuretics.htm">Diuretics</a></td><td><p><span>enhanced hypotensive effect when </span> <span>MAOIs</span> <span>given with</span> <span>diuretics</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int561-doxapram.htm">Doxapram</a></td><td><p><span></span> <span>MAOIs</span> <span>enhance effects of</span> <span>doxapram</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1024-duloxetine.htm">Duloxetine</a></td><td class="cAI"><p><span>after stopping </span> <span>MAOIs</span> <span>do not start</span> <span>duloxetine</span> <span>for 2 weeks, also <span>MAOIs</span> should not be started until at least 5 days after stopping <span>duloxetine</span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int854-entacapone.htm">Entacapone</a></td><td class="cAI"><p><span>avoid concomitant use of non-selective </span> <span>MAOIs</span> <span>with</span> <span>entacapone</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int964-escitalopram.htm">Escitalopram</a></td><td class="cAI"><p><span>after stopping </span> <span>MAOIs</span> <span>do not start</span> <span>escitalopram</span> <span>for 2 weeks, also <span>MAOIs</span> should not be started until at least 1 week after stopping <span>escitalopram</span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int234-fluoxetine.htm">Fluoxetine</a></td><td class="cAI"><p><span>after stopping </span> <span>MAOIs</span> <span>do not start</span> <span>fluoxetine</span> <span>for 2 weeks, also <span>MAOIs</span> should not be started until at least 5 weeks after stopping <span>fluoxetine</span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int235-fluvoxamine.htm">Fluvoxamine</a></td><td class="cAI"><p><span>after stopping </span> <span>MAOIs</span> <span>do not start</span> <span>fluvoxamine</span> <span>for 2 weeks, also <span>MAOIs</span> should not be started until at least 1 week after stopping <span>fluvoxamine</span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1180-histamine.htm">Histamine</a></td><td><p><span>avoidance of </span> <span>MAOIs</span> <span>advised by manufacturer of</span> <span>histamine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int763-hydralazine.htm">Hydralazine</a></td><td><p><span>enhanced hypotensive effect when </span> <span>MAOIs</span> <span>given with</span> <span>hydralazine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int28-indoramin.htm">Indoramin</a></td><td class="cAI"><p><span>avoidance of </span> <span>MAOIs</span> <span>advised by manufacturer of</span> <span>indoramin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int265-insulin.htm">Insulin</a></td><td><p><span></span> <span>MAOIs</span> <span>enhance hypoglycaemic effect of</span> <span>insulin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int558-levodopa.htm">Levodopa</a></td><td class="cAI"><p><span>risk of hypertensive crisis when </span> <span>MAOIs</span> <span>given with</span> <span>levodopa</span> <span>, avoid <span>levodopa</span> for at least 2 weeks after stopping <span>MAOIs</span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int257-maois.htm">MAOIs</a></td><td class="cAI"><p><span>increased risk of hypertension and CNS excitation when </span> <span>MAOIs</span> <span>given with other</span> <span>MAOIs</span> <span>(avoid for at least 2 weeks after stopping previous <span>MAOIs</span> and then start at a reduced dose)</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> For interactions of reversible MAO-A inhibitors (RIMAs) see Moclobemide, and for interactions of MAO-B inhibitors see Rasagiline and Selegiline; the antibacterial Linezolid is a reversible, non-selective MAO inhibitor</p></div></td></tr><tr><td><a href="bnf_int267-metformin.htm">Metformin</a></td><td><p><span></span> <span>MAOIs</span> <span>enhance hypoglycaemic effect of</span> <span>metformin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int611-methyldopa.htm">Methyldopa</a></td><td class="cAI"><p><span>avoidance of </span> <span>MAOIs</span> <span>advised by manufacturer of</span> <span>methyldopa</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int718-methylphenidate.htm">Methylphenidate</a></td><td class="cAI"><p><span>risk of hypertensive crisis when </span> <span>MAOIs</span> <span>given with</span> <span>methylphenidate</span> <span>, some manufacturers advise avoid <span>methylphenidate</span> for at least 2 weeks after stopping <span>MAOIs</span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int764-minoxidil.htm">Minoxidil</a></td><td><p><span>enhanced hypotensive effect when </span> <span>MAOIs</span> <span>given with</span> <span>minoxidil</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int823-mirtazapine.htm">Mirtazapine</a></td><td class="cAI"><p><span>after stopping </span> <span>MAOIs</span> <span>do not start</span> <span>mirtazapine</span> <span>for 2 weeks, also <span>MAOIs</span> should not be started until at least 2 weeks after stopping <span>mirtazapine</span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int262-moclobemide.htm">Moclobemide</a></td><td class="cAI"><p><span>after stopping </span> <span>MAOIs</span> <span>do not start</span> <span>moclobemide</span> <span>for at least 1 week</span>  </p></td><td></td></tr><tr><td><a href="bnf_int615-moxonidine.htm">Moxonidine</a></td><td><p><span>enhanced hypotensive effect when </span> <span>MAOIs</span> <span>given with</span> <span>moxonidine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int58-nefopam.htm">Nefopam</a></td><td class="cAI"><p><span>avoidance of </span> <span>MAOIs</span> <span>advised by manufacturer of</span> <span>nefopam</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int630-nicorandil.htm">Nicorandil</a></td><td><p><span>enhanced hypotensive effect when </span> <span>MAOIs</span> <span>given with</span> <span>nicorandil</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int631-nitrates.htm">Nitrates</a></td><td><p><span>enhanced hypotensive effect when </span> <span>MAOIs</span> <span>given with</span> <span>nitrates</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int85-opioid-analgesics.htm">Opioid Analgesics</a></td><td class="cAI"><p><span>possible CNS excitation or depression (hypertension or hypotension) when </span> <span>MAOIs</span> <span>given with</span> <span>opioid analgesics</span> <span>—some manufacturers advise avoid concomitant use and for 2 weeks after stopping <span>MAOIs</span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int236-paroxetine.htm">Paroxetine</a></td><td class="cAI"><p><span>after stopping </span> <span>MAOIs</span> <span>do not start</span> <span>paroxetine</span> <span>for 2 weeks, also <span>MAOIs</span> should not be started until at least 1 week after stopping <span>paroxetine</span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int102-pethidine.htm">Pethidine</a></td><td class="cAI"><p><span>CNS excitation or depression (hypertension or hypotension) when </span> <span>MAOIs</span> <span>given with</span> <span>pethidine</span> <span>—avoid concomitant use and for 2 weeks after stopping <span>MAOIs</span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1185-pholcodine.htm">Pholcodine</a></td><td><p><span>avoidance of pholcodine for 2 weeks after stopping </span> <span>MAOIs</span> <span>advised by manufacturer of</span> <span>pholcodine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int325-promethazine.htm">Promethazine</a></td><td><p><span>avoidance of promethazine for 2 weeks after stopping </span> <span>MAOIs</span> <span>advised by manufacturer of</span> <span>promethazine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1051-rasagiline.htm">Rasagiline</a></td><td class="cAI"><p><span>risk of hypertensive crisis when </span> <span>MAOIs</span> <span>given with</span> <span>rasagiline</span> <span>, avoid <span>MAOIs</span> for at least 2 weeks after stopping <span>rasagiline</span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Rasagiline is a MAO-B inhibitor</p></div></td></tr><tr><td><a href="bnf_int231-reboxetine.htm">Reboxetine</a></td><td class="cAI"><p><span>increased risk of hypertension and CNS excitation when </span> <span>MAOIs</span> <span>given with</span> <span>reboxetine</span> <span>(<span>MAOIs</span> should not be started until 1 week after stopping <span>reboxetine</span>, avoid <span>reboxetine</span> for 2 weeks after stopping <span>MAOIs</span>)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int862-rizatriptan.htm">Rizatriptan</a></td><td class="cAI"><p><span>risk of CNS toxicity when </span> <span>MAOIs</span> <span>given with</span> <span>rizatriptan</span> <span>(avoid <span>rizatriptan</span> for 2 weeks after <span>MAOIs</span>)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int687-selegiline.htm">Selegiline</a></td><td class="cAI"><p><span>enhanced hypotensive effect when </span> <span>MAOIs</span> <span>given with</span> <span>selegiline</span> <span>—manufacturer of <span>selegiline</span> advises avoid concomitant use</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Selegiline is a MAO-B inhibitor</p></div></td></tr><tr><td><a href="bnf_int237-sertraline.htm">Sertraline</a></td><td class="cAI"><p><span>after stopping </span> <span>MAOIs</span> <span>do not start</span> <span>sertraline</span> <span>for 2 weeks, also <span>MAOIs</span> should not be started until at least 1 week after stopping <span>sertraline</span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int765-sodium-nitroprusside.htm">Sodium Nitroprusside</a></td><td><p><span>enhanced hypotensive effect when </span> <span>MAOIs</span> <span>given with</span> <span>sodium nitroprusside</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int268-sulfonylureas.htm">Sulfonylureas</a></td><td><p><span></span> <span>MAOIs</span> <span>enhance hypoglycaemic effect of</span> <span>sulfonylureas</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int574-sumatriptan.htm">Sumatriptan</a></td><td class="cAI"><p><span>risk of CNS toxicity when </span> <span>MAOIs</span> <span>given with</span> <span>sumatriptan</span> <span>(avoid <span>sumatriptan</span> for 2 weeks after <span>MAOIs</span>)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int690-sympathomimetics.htm">Sympathomimetics</a></td><td class="cAI"><p><span>risk of hypertensive crisis when </span> <span>MAOIs</span> <span>given with</span> <span>sympathomimetics</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int733-tetrabenazine.htm">Tetrabenazine</a></td><td class="cAI"><p><span>risk of CNS toxicity when </span> <span>MAOIs</span> <span>given with</span> <span>tetrabenazine</span> <span>(avoid <span>tetrabenazine</span> for 2 weeks after <span>MAOIs</span>)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1042-tolcapone.htm">Tolcapone</a></td><td><p><span>avoid concomitant use of </span> <span>MAOIs</span> <span>with</span> <span>tolcapone</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int106-tramadol.htm">Tramadol</a></td><td class="cAI"><p><span>possible increased serotonergic effects and increased risk of convulsions when </span> <span>MAOIs</span> <span>given with</span> <span>tramadol</span> <span>—some manufacturers advise avoid concomitant use and for 2 weeks after stopping <span>MAOIs</span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int263-tryptophan.htm">Tryptophan</a></td><td class="cAI"><p><span>CNS excitation and confusion when </span> <span>MAOIs</span> <span>given with</span> <span>tryptophan</span> <span>(reduce dose of <span>tryptophan</span>)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int240-venlafaxine.htm">Venlafaxine</a></td><td class="cAI"><p><span>enhanced CNS effects and toxicity when </span> <span>MAOIs</span> <span>given with</span> <span>venlafaxine</span> <span>(<span>venlafaxine</span> should not be started until 2 weeks after stopping <span>MAOIs</span>, avoid <span>MAOIs</span> for 1 week after stopping <span>venlafaxine</span>)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int575-zolmitriptan.htm">Zolmitriptan</a></td><td class="cAI"><p><span>increased risk of CNS toxicity when </span> <span>MAOIs</span> <span>given with</span> <span>zolmitriptan</span> <span></span>  </p></td><td></td></tr></tbody></table><p><strong>Isocarboxazid</strong> belongs to <strong>Antidepressants</strong> but has no specific interaction information.</p><p><strong>Phenelzine</strong> belongs to <strong>Antidepressants</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int628-suxamethonium.htm">Suxamethonium</a></td><td><p><span></span> <span>phenelzine</span> <span>enhances effects of</span> <span>suxamethonium</span> <span></span>  </p></td><td></td></tr></tbody></table><p><strong>Tranylcypromine</strong> belongs to <strong>Antidepressants</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int427-buspirone.htm">Buspirone</a></td><td><p><span>manufacturer of </span> <span>tranylcypromine</span> <span>advises avoid</span> <span>buspirone</span> <span>for 10 days after stopping <span>tranylcypromine</span></span>  </p></td><td></td></tr></tbody></table><p><strong>MAOIs, reversible</strong> belongs to <strong>Antidepressants</strong> but has no specific interaction information.</p><p><strong>Moclobemide</strong> belongs to <strong>Antidepressants</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int238-antidepressants-ssri-related.htm">Antidepressants, SSRI (related)</a></td><td class="cAI"><p><span></span> <span>moclobemide</span> <span>should not be started for at least 1 week after stopping</span> <span>SSRI-related antidepressants</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int241-antidepressants-tricyclic.htm">Antidepressants, Tricyclic</a></td><td class="cAI"><p><span></span> <span>moclobemide</span> <span>should not be started for at least 1 week after stopping</span> <span>tricyclics</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int252-antidepressants-tricyclic-related.htm">Antidepressants, Tricyclic (related)</a></td><td class="cAI"><p><span></span> <span>moclobemide</span> <span>should not be started for at least 1 week after stopping</span> <span>tricyclic-related antidepressants</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int896-bupropion.htm">Bupropion</a></td><td class="cAI"><p><span>avoidance of </span> <span>moclobemide</span> <span>advised by manufacturer of</span> <span>bupropion</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int744-cimetidine.htm">Cimetidine</a></td><td><p><span>plasma concentration of </span> <span>moclobemide</span> <span>increased by</span> <span>cimetidine</span> <span>(halve dose of <span>moclobemide</span>)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int233-citalopram.htm">Citalopram</a></td><td class="cAI"><p><span></span> <span>moclobemide</span> <span>should not be started for at least 1 week after stopping</span> <span>citalopram</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int865-clopidogrel.htm">Clopidogrel</a></td><td class="cAI"><p><span></span> <span>moclobemide</span> <span>possibly reduces antiplatelet effect of</span> <span>clopidogrel</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int882-dextromethorphan.htm">Dextromethorphan</a></td><td class="cAI"><p><span>possible CNS excitation or depression (hypertension or hypotension) when </span> <span>moclobemide</span> <span>given with</span> <span>dextromethorphan</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1024-duloxetine.htm">Duloxetine</a></td><td class="cAI"><p><span>possible increased serotonergic effects when </span> <span>moclobemide</span> <span>given with</span> <span>duloxetine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int854-entacapone.htm">Entacapone</a></td><td><p><span>caution with </span> <span>moclobemide</span> <span>advised by manufacturer of</span> <span>entacapone</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int964-escitalopram.htm">Escitalopram</a></td><td class="cAI"><p><span>increased risk of CNS toxicity when </span> <span>moclobemide</span> <span>given with</span> <span>escitalopram</span> <span>, preferably avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int234-fluoxetine.htm">Fluoxetine</a></td><td class="cAI"><p><span></span> <span>moclobemide</span> <span>should not be started until 5 weeks after stopping</span> <span>fluoxetine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int235-fluvoxamine.htm">Fluvoxamine</a></td><td class="cAI"><p><span></span> <span>moclobemide</span> <span>should not be started for at least 1 week after stopping</span> <span>fluvoxamine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int558-levodopa.htm">Levodopa</a></td><td><p><span>increased risk of side-effects when </span> <span>moclobemide</span> <span>given with</span> <span>levodopa</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int257-maois.htm">MAOIs</a></td><td class="cAI"><p><span></span> <span>moclobemide</span> <span>should not be started for at least 1 week after stopping</span> <span>MAOIs</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> For interactions of reversible MAO-A inhibitors (RIMAs) see Moclobemide, and for interactions of MAO-B inhibitors see Rasagiline and Selegiline; the antibacterial Linezolid is a reversible, non-selective MAO inhibitor</p></div></td></tr><tr><td><a href="bnf_int823-mirtazapine.htm">Mirtazapine</a></td><td class="cAI"><p><span></span> <span>moclobemide</span> <span>should not be started for at least 1 week after stopping</span> <span>mirtazapine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int85-opioid-analgesics.htm">Opioid Analgesics</a></td><td class="cAI"><p><span>possible CNS excitation or depression (hypertension or hypotension) when </span> <span>moclobemide</span> <span>given with</span> <span>opioid analgesics</span> <span>—manufacturer of <span>moclobemide</span> advises consider reducing dose of <span>opioid analgesics</span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int236-paroxetine.htm">Paroxetine</a></td><td class="cAI"><p><span></span> <span>moclobemide</span> <span>should not be started for at least 1 week after stopping</span> <span>paroxetine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int102-pethidine.htm">Pethidine</a></td><td class="cAI"><p><span>possible CNS excitation or depression (hypertension or hypotension) when </span> <span>moclobemide</span> <span>given with</span> <span>pethidine</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int862-rizatriptan.htm">Rizatriptan</a></td><td class="cAI"><p><span>risk of CNS toxicity when </span> <span>moclobemide</span> <span>given with</span> <span>rizatriptan</span> <span>(avoid <span>rizatriptan</span> for 2 weeks after <span>moclobemide</span>)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int687-selegiline.htm">Selegiline</a></td><td class="cAI"><p><span>avoid concomitant use of </span> <span>moclobemide</span> <span>with</span> <span>selegiline</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Selegiline is a MAO-B inhibitor</p></div></td></tr><tr><td><a href="bnf_int237-sertraline.htm">Sertraline</a></td><td class="cAI"><p><span></span> <span>moclobemide</span> <span>should not be started for at least 1 week after stopping</span> <span>sertraline</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int574-sumatriptan.htm">Sumatriptan</a></td><td class="cAI"><p><span>risk of CNS toxicity when </span> <span>moclobemide</span> <span>given with</span> <span>sumatriptan</span> <span>(avoid <span>sumatriptan</span> for 2 weeks after <span>moclobemide</span>)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int690-sympathomimetics.htm">Sympathomimetics</a></td><td class="cAI"><p><span>risk of hypertensive crisis when </span> <span>moclobemide</span> <span>given with</span> <span>sympathomimetics</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int575-zolmitriptan.htm">Zolmitriptan</a></td><td class="cAI"><p><span>risk of CNS toxicity when </span> <span>moclobemide</span> <span>given with</span> <span>zolmitriptan</span> <span>(reduce dose of <span>zolmitriptan</span>)</span>  </p></td><td></td></tr></tbody></table><p><strong>St John's Wort</strong> belongs to <strong>Antidepressants</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int572-5ht-1-receptor-agonists.htm">5HT<sub>1</sub>-receptor Agonists</a></td><td class="cAI"><p><span>increased serotonergic effects when </span> <span>St John's wort</span> <span>given with</span> <span>5HT<sub>1</sub> agonists</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int242-amitriptyline.htm">Amitriptyline</a></td><td><p><span></span> <span>St John's wort</span> <span>reduces plasma concentration of</span> <span>amitriptyline</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int470-amlodipine.htm">Amlodipine</a></td><td><p><span></span> <span>St John's wort</span> <span>possibly reduces plasma concentration of</span> <span>amlodipine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int232-antidepressants-ssri.htm">Antidepressants, SSRI</a></td><td class="cAI"><p><span>increased serotonergic effects when </span> <span>St John's wort</span> <span>given with</span> <span>SSRIs</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int276-antiepileptics.htm">Antiepileptics</a></td><td class="cAI"><p><span>avoid concomitant use of </span> <span>St John's wort</span> <span>with</span> <span>antiepileptics</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1010-aprepitant.htm">Aprepitant</a></td><td class="cAI"><p><span>avoidance of </span> <span>St John's wort</span> <span>advised by manufacturer of</span> <span>aprepitant</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1011-aripiprazole.htm">Aripiprazole</a></td><td class="cAI"><p><span></span> <span>St John's wort</span> <span>possibly reduces plasma concentration of</span> <span>aripiprazole</span> <span>—increase dose of <span>aripiprazole</span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1005-atazanavir.htm">Atazanavir</a></td><td class="cAI"><p><span></span> <span>St John's wort</span> <span>reduces plasma concentration of</span> <span>atazanavir</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1204-cabazitaxel.htm">Cabazitaxel</a></td><td class="cAI"><p><span>avoidance of </span> <span>St John's wort</span> <span>advised by manufacturer of</span> <span>cabazitaxel</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int499-ciclosporin.htm">Ciclosporin</a></td><td class="cAI"><p><span></span> <span>St John's wort</span> <span>reduces plasma concentration of</span> <span>ciclosporin</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int220-coumarins.htm">Coumarins</a></td><td class="cAI"><p><span></span> <span>St John's wort</span> <span>reduces anticoagulant effect of</span> <span>coumarins</span> <span>(avoid concomitant use)</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Change in patient's clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</p></div></td></tr><tr><td><a href="bnf_int1120-dabigatran-etexilate.htm">Dabigatran Etexilate</a></td><td><p><span></span> <span>St John's wort</span> <span>possibly reduces plasma concentration of</span> <span>dabigatran etexilate</span> <span>—manufacturer of <span>dabigatran etexilate</span> advises avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1091-darunavir.htm">Darunavir</a></td><td class="cAI"><p><span></span> <span>St John's wort</span> <span>reduces plasma concentration of</span> <span>darunavir</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int480-digoxin.htm">Digoxin</a></td><td class="cAI"><p><span></span> <span>St John's wort</span> <span>reduces plasma concentration of</span> <span>digoxin</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1176-dronedarone.htm">Dronedarone</a></td><td class="cAI"><p><span></span> <span>St John's wort</span> <span>possibly reduces plasma concentration of</span> <span>dronedarone</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1024-duloxetine.htm">Duloxetine</a></td><td><p><span>possible increased serotonergic effects when </span> <span>St John's wort</span> <span>given with</span> <span>duloxetine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int874-efavirenz.htm">Efavirenz</a></td><td class="cAI"><p><span></span> <span>St John's wort</span> <span>reduces plasma concentration of</span> <span>efavirenz</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1025-eplerenone.htm">Eplerenone</a></td><td class="cAI"><p><span></span> <span>St John's wort</span> <span>reduces plasma concentration of</span> <span>eplerenone</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1205-eribulin.htm">Eribulin</a></td><td><p><span></span> <span>St John's wort</span> <span>possibly reduces plasma concentration of</span> <span>eribulin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1135-etravirine.htm">Etravirine</a></td><td><p><span>avoidance of </span> <span>St John's wort</span> <span>advised by manufacturer of</span> <span>etravirine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1169-everolimus.htm">Everolimus</a></td><td><p><span></span> <span>St John's wort</span> <span>possibly reduces plasma concentration of</span> <span>everolimus</span> <span>—manufacturer of <span>everolimus</span> advises avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1019-fosamprenavir.htm">Fosamprenavir</a></td><td class="cAI"><p><span></span> <span>St John's wort</span> <span>reduces plasma concentration of</span> <span>fosamprenavir</span> <span>—avoid concomitant use</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Fosamprenavir is a prodrug of amprenavir</p></div></td></tr><tr><td><a href="bnf_int1170-gefitinib.htm">Gefitinib</a></td><td><p><span>avoidance of </span> <span>St John's wort</span> <span>advised by manufacturer of</span> <span>gefitinib</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int933-imatinib.htm">Imatinib</a></td><td class="cAI"><p><span></span> <span>St John's wort</span> <span>reduces plasma concentration of</span> <span>imatinib</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int398-indinavir.htm">Indinavir</a></td><td class="cAI"><p><span></span> <span>St John's wort</span> <span>reduces plasma concentration of</span> <span>indinavir</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1006-irinotecan.htm">Irinotecan</a></td><td class="cAI"><p><span></span> <span>St John's wort</span> <span>accelerates metabolism of</span> <span>irinotecan</span> <span>(reduced plasma  concentration—avoid concomitant use)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1050-ivabradine.htm">Ivabradine</a></td><td><p><span></span> <span>St John's wort</span> <span>reduces plasma concentration of</span> <span>ivabradine</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1128-lapatinib.htm">Lapatinib</a></td><td class="cAI"><p><span>avoidance of </span> <span>St John's wort</span> <span>advised by manufacturer of</span> <span>lapatinib</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int922-lopinavir.htm">Lopinavir</a></td><td class="cAI"><p><span></span> <span>St John's wort</span> <span>reduces plasma concentration of</span> <span>lopinavir</span> <span>—avoid concomitant use</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> In combination with ritonavir as Kaletra® (ritonavir is present to inhibit lopinavir metabolism and increase plasma-lopinavir concentration)—see also Ritonavir</p></div></td></tr><tr><td><a href="bnf_int1107-maraviroc.htm">Maraviroc</a></td><td class="cAI"><p><span></span> <span>St John's wort</span> <span>possibly reduces plasma concentration of</span> <span>maraviroc</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int97-methadone.htm">Methadone</a></td><td><p><span></span> <span>St John's wort</span> <span>possibly reduces plasma concentration of</span> <span>methadone</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int421-midazolam.htm">Midazolam</a></td><td><p><span></span> <span>St John's wort</span> <span>possibly reduces plasma concentration of oral</span> <span>midazolam</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int842-nelfinavir.htm">Nelfinavir</a></td><td class="cAI"><p><span></span> <span>St John's wort</span> <span>reduces plasma concentration of</span> <span>nelfinavir</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int843-nevirapine.htm">Nevirapine</a></td><td class="cAI"><p><span></span> <span>St John's wort</span> <span>reduces plasma concentration of</span> <span>nevirapine</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int475-nifedipine.htm">Nifedipine</a></td><td><p><span></span> <span>St John's wort</span> <span>reduces plasma concentration of</span> <span>nifedipine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int636-oestrogens.htm">Oestrogens</a></td><td class="cAI"><p><span></span> <span>St John's wort</span> <span>reduces contraceptive effect of</span> <span>oestrogens</span> <span>(avoid concomitant use)</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Interactions of combined oral contraceptives may also apply to combined contraceptive patches and vaginal rings, see <a title="COCs interactions (target-block)" href="PHP4869-combined-hormonal-contraceptives.htm#PHP4875">section 7.3.1</a></p></div></td></tr><tr><td><a href="bnf_int752-omeprazole.htm">Omeprazole</a></td><td><p><span></span> <span>St John's wort</span> <span>possibly reduces plasma concentration of</span> <span>omeprazole</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int664-progestogens.htm">Progestogens</a></td><td class="cAI"><p><span></span> <span>St John's wort</span> <span>reduces contraceptive effect of</span> <span>progestogens</span> <span>(avoid concomitant use)</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Interactions of combined oral contraceptives may also apply to combined contraceptive patches and vaginal rings, see <a href="PHP4869-combined-hormonal-contraceptives.htm#PHP4875">section 7.3.1</a>. For further information on interactions of oral progestogen-only contraceptives, see also <a href="PHP4944-oral-progestogen-only-contraceptives.htm#PHP4945">section 7.3.2.1</a>; parenteral progestogen-only contraceptives, see also <a href="PHP4960-parenteral-progestogen-only-contraceptives.htm#PHP4965">section 7.3.2.2</a>; the intra-uterine progestogen-only device, see also <a href="PHP4973-intra-uterine-progestogen-only-device.htm#PHP4974">section 7.3.2.3</a>; hormonal emergency contraception, see also <a href="PHP5019-hormonal-methods.htm#PHP5024">section 7.3.5</a></p></div></td></tr><tr><td><a href="bnf_int1225-rilpivirine.htm">Rilpivirine</a></td><td class="cAI"><p><span>avoidance of </span> <span>St John's wort</span> <span>advised by manufacturer of</span> <span>rilpivirine</span> <span>(plasma concentration of <span>rilpivirine</span> possibly reduced)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int400-ritonavir.htm">Ritonavir</a></td><td class="cAI"><p><span></span> <span>St John's wort</span> <span>reduces plasma concentration of</span> <span>ritonavir</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int791-saquinavir.htm">Saquinavir</a></td><td class="cAI"><p><span></span> <span>St John's wort</span> <span>reduces plasma concentration of</span> <span>saquinavir</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int605-simvastatin.htm">Simvastatin</a></td><td><p><span></span> <span>St John's wort</span> <span>reduces plasma concentration of</span> <span>simvastatin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int730-tacrolimus.htm">Tacrolimus</a></td><td class="cAI"><p><span></span> <span>St John's wort</span> <span>reduces plasma concentration of</span> <span>tacrolimus</span> <span>—avoid concomitant use</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Interactions do not generally apply to tacrolimus used topically; risk of facial flushing and skin irritation with alcohol consumption (<a title="monograph: TACROLIMUS" href="PHP7780-tacrolimus.htm">see section 13.5.3</a>) does not apply to tacrolimus taken systemically</p></div></td></tr><tr><td><a href="bnf_int1216-telaprevir.htm">Telaprevir</a></td><td class="cAI"><p><span>avoidance of </span> <span>St John's wort</span> <span>advised by manufacturer of</span> <span>telaprevir</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int946-telithromycin.htm">Telithromycin</a></td><td class="cAI"><p><span></span> <span>St John's wort</span> <span>reduces plasma concentration of</span> <span>telithromycin</span> <span>(avoid during and for 2 weeks after <span>St John's wort</span>)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int734-theophylline.htm">Theophylline</a></td><td class="cAI"><p><span></span> <span>St John's wort</span> <span>reduces plasma concentration of</span> <span>theophylline</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1055-tipranavir.htm">Tipranavir</a></td><td class="cAI"><p><span></span> <span>St John's wort</span> <span>possibly reduces plasma concentration of</span> <span>tipranavir</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1163-ulipristal.htm">Ulipristal</a></td><td class="cAI"><p><span>avoidance of </span> <span>St John's wort</span> <span>advised by manufacturer of</span> <span>ulipristal</span> <span>(contraceptive effect of <span>ulipristal</span> possibly reduced)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1227-vandetanib.htm">Vandetanib</a></td><td><p><span>avoidance of </span> <span>St John's wort</span> <span>advised by manufacturer of</span> <span>vandetanib</span> <span>(plasma concentration of <span>vandetanib</span> possibly reduced)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1229-vemurafenib.htm">Vemurafenib</a></td><td><p><span>avoidance of </span> <span>St John's wort</span> <span>advised by manufacturer of</span> <span>vemurafenib</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int240-venlafaxine.htm">Venlafaxine</a></td><td><p><span>possible increased serotonergic effects when </span> <span>St John's wort</span> <span>given with</span> <span>venlafaxine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int467-verapamil.htm">Verapamil</a></td><td class="cAI"><p><span></span> <span>St John's wort</span> <span>significantly reduces plasma concentration of</span> <span>verapamil</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1181-vinflunine.htm">Vinflunine</a></td><td class="cAI"><p><span></span> <span>St John's wort</span> <span>possibly reduces plasma concentration of</span> <span>vinflunine</span> <span>—manufacturer of <span>vinflunine</span> advises avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int948-voriconazole.htm">Voriconazole</a></td><td class="cAI"><p><span></span> <span>St John's wort</span> <span>reduces plasma concentration of</span> <span>voriconazole</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr></tbody></table><p><strong>Tryptophan</strong> belongs to <strong>Antidepressants</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int232-antidepressants-ssri.htm">Antidepressants, SSRI</a></td><td class="cAI"><p><span>agitation and nausea may occur when </span> <span>tryptophan</span> <span>given with</span> <span>SSRIs</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1024-duloxetine.htm">Duloxetine</a></td><td><p><span>possible increased serotonergic effects when </span> <span>tryptophan</span> <span>given with</span> <span>duloxetine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int234-fluoxetine.htm">Fluoxetine</a></td><td><p><span>CNS toxicity reported when </span> <span>tryptophan</span> <span>given with</span> <span>fluoxetine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int257-maois.htm">MAOIs</a></td><td class="cAI"><p><span>CNS excitation and confusion when </span> <span>tryptophan</span> <span>given with</span> <span>MAOIs</span> <span>(reduce dose of <span>tryptophan</span>)</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> For interactions of reversible MAO-A inhibitors (RIMAs) see Moclobemide, and for interactions of MAO-B inhibitors see Rasagiline and Selegiline; the antibacterial Linezolid is a reversible, non-selective MAO inhibitor</p></div></td></tr></tbody></table></div><div id="pS"><p>Sub-sections</p><ul class="jT"><li><a href="bnf_int1145-agomelatine.htm" title="Agomelatine">Agomelatine</a></li><li><a href="bnf_int823-mirtazapine.htm" title="Mirtazapine">Mirtazapine</a></li><li id="_bnf_int230-antidepressants-noradrenaline-re-uptake-inhibitors"><a href="bnf_int230-antidepressants-noradrenaline-re-uptake-inhibitors.htm" title="Antidepressants, Noradrenaline Re-uptake Inhibitors">Antidepressants, Noradrenaline Re-uptake Inhibitors</a></li><li id="_bnf_int232-antidepressants-ssri"><a href="bnf_int232-antidepressants-ssri.htm" title="Antidepressants, SSRI">Antidepressants, SSRI</a></li><li id="_bnf_int238-antidepressants-ssri-related"><a href="bnf_int238-antidepressants-ssri-related.htm" title="Antidepressants, SSRI (related)">Antidepressants, SSRI (related)</a></li><li id="_bnf_int241-antidepressants-tricyclic"><a href="bnf_int241-antidepressants-tricyclic.htm" title="Antidepressants, Tricyclic">Antidepressants, Tricyclic</a></li><li id="_bnf_int252-antidepressants-tricyclic-related"><a href="bnf_int252-antidepressants-tricyclic-related.htm" title="Antidepressants, Tricyclic (related)">Antidepressants, Tricyclic (related)</a></li><li id="_bnf_int257-maois"><a href="bnf_int257-maois.htm" title="MAOIs">MAOIs</a></li><li id="_bnf_int261-maois-reversible"><a href="bnf_int261-maois-reversible.htm" title="MAOIs, reversible">MAOIs, reversible</a></li><li><a href="bnf_int905-st-johns-wort.htm" title="St John's Wort">St John's Wort</a></li><li><a href="bnf_int263-tryptophan.htm" title="Tryptophan">Tryptophan</a></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="bnf_int228-tinzaparin.htm">Previous: Tinzaparin</a> | <a class="top" href="bnf_int229-antidepressants.htm#">Top</a> | <a accesskey="]" href="bnf_int1145-agomelatine.htm">Next: Agomelatine</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Cookie and Privacy Policy">Cookie and Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="PHP0-publication-information.htm" rel="copyright">Copyright © BMJ Group and Pharmaceutical Press 2012. All rights reserved. </a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>